

Review

Recommendations to Synthesize Old and New β -Lactamases Inhibitors: A Review to Encourage Further Production

Silvana Alfei *  and Guendalina Zuccari 

Department of Pharmacy (DIFAR), University of Genoa, Viale Cembrano, 16148 Genoa, Italy; zuccari@difar.unige.it

* Correspondence: alfei@difar.unige.it; Tel.: +39-010-355-2296

Abstract: The increasing emergence of bacteria producing β -lactamases enzymes (BLEs), able to inactivate the available β -lactam antibiotics (BLAs), causing the hydrolytic opening of their β -lactam ring, is one of the global major warnings. According to Ambler classification, BLEs are grouped in serine-BLEs (SBLEs) of class A, C, and D, and metal-BLEs (MBLEs) of class B. A current strategy to restore no longer functioning BLAs consists of associating them to β -lactamase enzymes inhibitors (BLEsIs), which, interacting with BLEs, prevent them hydrolyzing to the associated antibiotic. Worryingly, the inhibitors that are clinically approved are very few and inhibit only most of class A and C SBLEs, leaving several class D and all MBLEs of class B untouched. Numerous non-clinically approved new molecules are in development, which have shown broad and ultra-broad spectrum of action, some of them also being active on the New Delhi metal- β -lactamase-1 (NDM-1), which can hydrolyze all available BLAs except for aztreonam. To not duplicate the existing review concerning this topic, we have herein examined BLEsIs by a chemistry approach. To this end, we have reviewed both the long-established synthesis adopted to prepare the old BLEsIs, those proposed to achieve the BLEsIs that are newly approved, and those recently reported to prepare the most relevant molecules yet in development, which have shown high potency, providing for each synthesis the related reaction scheme.

Keywords: optimized synthetic procedures; β -lactam antibiotics; β -lactamase enzymes; β -lactamase enzymes inhibitors; multi-drug resistant (MDR) bacteria; serine β -lactamases; metal- β -lactamases

**Citation:** Alfei, S.; Zuccari, G.Recommendations to Synthesize Old and New β -Lactamases Inhibitors: A Review to Encourage Further Production. *Pharmaceuticals* **2022**, *15*, 384. <https://doi.org/10.3390/ph15030384>

Academic Editor: Paweł Kafarski

Received: 11 February 2022

Accepted: 19 March 2022

Published: 21 March 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

The chemical structure of β -lactam antibiotics (BLAs) used to treat a large variety of infections [1] comprises a bicyclic or monocyclic structure. In both cases, a four-term β -lactam nucleus is present, which embodies the weak point of these drugs, being the target of β -lactamase enzymes (BLEs). BLEs are enzymes produced by an increasing number of clinically relevant bacteria as defensive strategy against BLAs. Specifically, they catalyse the hydrolysis and inactivating opening of the four-membered β -lactam cycle [2].

The most established strategy to prevent the hydrolytic activity of BLEs consists of developing BLEs inhibitors (BLEsIs), generally free of intrinsic antibacterial effects. These molecules, when administered in associations with already existing BLAs no longer functioning, can protect them, thus allowing them to recover their original activity.

The currently available classes of BLAs derive from structural modifications of the natural penicillin, executed to prepare semisynthetic antibiotics with increasingly enhanced characteristics, and capable of circumventing the emergence of bacterial resistance [1]. Bicyclic nuclei are present in penicillin-like BLAs, cephalosporins, and carbapenems, while monocyclic systems are typical of monobactams. Particularly, penicillin and derivatives shown in Figure 1a,b have a four-membered β -lactam ring fused to a five-membered ring [1,2]. Compound (1) shows the correct numbering of the basic system, which can be applied also to compounds (2), (3), (4), (5), and (6). Cephalosporins and derivatives are

characterized by a six-membered ring fused with the β -lactam nucleus (Figure 1c,d), while a monocyclic nucleus and a sulphonic acid group on the nitrogen atom of the cyclic amide typifies monobactams (Figure 1e) [1,2]. Compound (7) shows the correct numbering of the basic system, which can be applied also to compounds (8), (9), (10), (11), and (12), while the correct numbering of the monobactam system has been shown on compound (13).




Figure 1. The β -lactam core structures. Penams (1), carbapenams (2), oxapenams (3) (a); penams (4), carbapenams (5), oxapenams (6) (b); cephems (7), carbacephems (8), oxacephem (9) (c); cepham (10), carbacepham (11), oxacephem (12) (d); monobactam (13) (e).

More generically, penicillins having a thiazolidine five membered ring are named penams. Logically, penicillin derivatives in which the sulfur atom has been substituted by an oxygen atom are named oxapenams, and those having a carbon atom in place of the sulfur one are named carbapenams (Figure 1a, compounds (1), (2), and (3)). The derivatives of penams, carbapenams, and oxapenams having double bonds (C=C) in

position 2–3 in the five-terms rings create the families of penems, carbapenems, and oxapenems (Figure 1b, compounds (4), (5), and (6)). Cephalosporins, which have double bonds in position 2–3 in the six-terms ring, are named cephems, therefore their derivatives obtainable by changing the sulfur atom with a carbon atom or with an oxygen one generate the families of carbacephem and oxacephem, respectively (Figure 1c, compounds (7), (8), and (9)). Finally, the correspondent saturated derivatives engender the families of cepham, carbacepham, and oxacepham (Figure 1d, compounds (10), (11), and (12) [3].

The mechanism of action of BLAs involves their deactivating interaction with a set of D-alanyl-D-alanine transpeptidases enzymes, identified as penicillin binding proteins (PBPs), which catalyse the synthesis of the peptidoglycan layer of the bacterial cell wall [4]. Without functioning PBPs, the synthesis of peptidoglycan cannot occur, bacteria cannot grow, and consequently they die [5]. While bicyclic BLAs, such as penicillin and cephalosporin, have a broad spectrum of action, which includes both Gram-positive and Gram-negative bacteria, the monobactams are specifically active against aerobic isolates of Gram-negative species [6,7]. Importantly, carbapenems are effective against both Gram-positive and Gram-negative, also including multidrug resistant (MDR) bacteria. Nowadays, carbapenems constitute an essential group of antibiotics for the treatment of severe infections caused by frightening super-bugs, resistant to the most part of traditional antibiotics [8]. Structurally, as above mentioned, carbapenems are bicyclic β -lactam molecules like penicillin, but having a carbon atom in position 4 in place of the sulphur atom of penicillin and containing a C2-C3 double bond, they are more resistant to the hydrolytic attack of the most part of BLEs (Figure 2) [5].




Figure 2. Chemical structure of carbapenems.

Concerning the available antibacterial armamentarium, in terms of β -lactam antibiotics, the main types of BLAs developed until now have been reported in Table 1, constructed using the public information provided online at https://en.wikipedia.org/wiki/List_of_%CE%B2-lactam_antibiotics# (accessed on 10 February 2022) [3].

Unfortunately, to challenge the dangerous action of BLAs, bacteria are increasingly developing resistance by different mechanisms, including the hyper-expression of efflux pumps, the down regulation of the expression of porins, the alteration of PBPs and, above all, the production of β -lactamase enzymes (BLEs), which inactivate BLAs [9,10].

Particularly, BLEs can hydrolyse the β -lactam amide bond present in the four-terms cycle of BLAs. This process causes the ring opening and other irreversible molecular modifications, thus leading to ineffective products, because they are no longer capable of interacting with PBPs [5]. Based on the structural features of their active-site, BLEs have been classified in serine BLEs (SBLEs) [11] and in metallo-BLEs (MBLEs). The latter ones possess a very broad spectrum of action, and nowadays, although particularly in Asia, they are disseminated worldwide [12,13]. According to the Ambler classification, SBLEs have been grouped into class A, C, and D, while MBLEs give rise to the BLEs of class B [1,14–16].

Table 1. The most relevant BLAs developed until now.

Penicillins	Narrow spectrum	β -lactamase sensitive (1st generation)	benzylpenicillin (G) # benzathine benzylpenicillin # procaine benzylpenicillin # phenoxymethylpenicillin (V) # propicillin †, pheneticillin † azidocillin †, clometocillin † penamecillin †
		β -lactamase resistant (2nd generation)	cloxacillin #, dicloxacillin flucloxacillin; oxacillin; nafcillin methicillin †
	Extended spectrum	aminopenicillins (3rd generation)	amoxicillin # ampicillin #; pivampicillin hetacillin †; bacampicillin † metampicillin †; talampicillin † epicillin †
		carboxypenicillins (4th generation)	ticarcillin carbenicillin †; carindacillin † temocillin †
		ureidopenicillins (4th generation)	piperacillin; azlocillin †; mezlocillin †
		Others	mecillinam; pivmecillinam, sulbenicillin †
(BLAs) *	carbapenems	ertapenem ¹ ; doripenem ² ; imipenem ² ; meropenem ² ; biapenem †; panipenem faropenem ³ ; ritipenem ^{3,§}	
cephems cephalosporins cephamycins carbacephems	1st generation	cefazolin #; cefalexin #; cefadroxil; cefapirin; cefazedone † cefazaflur; cefradine †; cefroxadine †; ceftazole †; cefalglycin † cefacetriole †; cefalonium †; cefaloridine †; cefalotin; cefatrizine †	
	2nd generation	cefaclor, cefprozil, cefuroxime, cefuroxime axetil, cefamandole †, cefonicid †; ceforanide †; cefuzonam †; cefoxitin, cefotetan cefminox †; cefbuperazone †; cefmetazole †; loracarbef †	
	3rd generation	cefixime #; ceftriaxone #; cefotaxime #; ceftazidime #,2; cefoperazone †,2 cefdinir; cefcapene; cefdaloxime; ceftizoxime; cefmenoxime cefpiramide; cefpodoxime; ceftibuten; cefditoren; cefotiam † cefetamet †; cefodizime †; cefpimizole †; cefsulodin †; cefteteram † ceftiolele †; flomoxef †; latamoxef †	
	4th generation	cefepime; ceftazopran †; cefpirome; cefquinome †	
	5th generation	ceftaroline fosamil; ceftolozane; ceftobiprole	
	siderophore	cefiderocol #	
	veterinary	ceftiofur; cefquinome; ceftiovecin	
monobactams	aztreonam, tigemonam †; carumonam †; nocardicin A †		

* β -lactam antibiotics; # WHO-EM = The World Health Organization model list of essential medicines, which is published by the WHO, and contains the medications considered to be most effective and safe to meet the most important needs in a health system; † withdrawn from market; ¹ carbapenems; ² antipseudomonal; ³ penems; [§] never to phase III clinical trials.

Initially, SBLEs were capable of hydrolysing only the first generation BLAs, such as narrow and broad-spectrum penicillin and penicillin derivatives. Therefore, the development of extended spectrum cephalosporins of different generations (cefotaxime, ceftriaxone, and ceftazidime) allowed to counteract severe infections by bacteria producing such enzymes. In a second moment, the emergence of extended spectrum SBLEs (ESSBLEs), also capable of hydrolysing the β -lactam ring of cephalosporines, dramatically reduced the therapeutic potential of the available antibacterial armamentarium. In this contest, the development of carbapenems, which displayed a wider spectrum of action, and were capable to resist the hydrolytic action of several ESSBLEs, were also effective against alarming bacteria producing ESSBLEs, and their clinical application strongly increased in the 2000s [17]. Carbapenems, including the longest established imipenem, meropenem, and ertapenem, and the recently developed doripenem, biapenem, panipenem, razupenem, and tomopenem [17], in addition to resist the inactivating action of the first generations of ESSBLEs, demonstrated their ability to also act as inhibitors for many ESSBLEs [18–20].


However, the excessive and inappropriate continued use of BLAs has selected, in the past, decade bacteria that is also resistant to carbapenems, including doripenem, ertapenem, imipenem, and meropenem [8,21,22], due to their capability to produce both new ESSBLEs capable to also hydrolyse carbapenems and carbapenem-hydrolysing MBLEs of group B [23–25]. Additionally, the reduction of membrane porins, the improvement in number of efflux pumps [23], the alteration of PBPs (PBP2 or PBP3), and the hyperexpression of class C AmpCs are supplementary processes involved in the resistance of bacteria to carbapenems [26,27]. Specifically, the global worry mainly regards the proliferation of certain types of bacteria resistant to carbapenems, which includes those capable of producing the *Klebsiella pneumoniae* carbapenemases (KPCs) belonging to the ESSBLEs of class A, the oxacillinases (OXAs) belonging to the ESSBLEs of class D, and above all the New Delhi metallo- β -lactamases (NDMs and mostly NDM-1) belonging to MBLEs of class B [1,16]. Notably, NDMs are a subclass of recently identified enzymes which makes bacteria resistant to a broad spectrum of BLAs, including carbapenems family, which have been a staple for the treatment of antibiotic-resistant bacteria.

In the list published by the WHO in the year 2017, carbapenem-resistant *Acinetobacter baumannii* (CRAB), carbapenems-resistant *Pseudomonas aeruginosa* (CRPA), as well as carbapenem- and third generation cephalosporin-resistant *Enterobacteriaceae* (CRE), were inserted in the highest category of urgency [28]. The long-established strategy to prevent the resistance to BLAs, due to the increasing diffusion of bacteria producing BLEs, consists of developing BLEs inhibitors (BLEsIs) to administer in associations with already existing BLAs for preventing their inactivation. The discovery and subsequent commercialization of first generation β -lactam-type BLEsIs, such as clavulanic acid, sulbactam, and tazobactam, strongly ameliorated the alarming scenario of the antimicrobial therapy. Despite being free of any antibacterial effect, when co-administered with no longer functioning BLAs, such BLEsIs allowed them to recover their original activity. Combinations including amoxicillin/clavulanic acid, ampicillin/sulbactam, and piperacillin/tazobactam have been successfully used over a long period and are currently in use [16,22]. Unfortunately, the activity of these inhibitors is limited mainly to the BLEs of class A, not including carbapenemases, and is weak against class C BLEs and absent against carbapenemases of group B and D. Consequently, due to the increasing emergence and diffusion of serine carbapenemases of class A and D, such as KPCs and OXAs, respectively, and carbapenemases of class B, such as NDMs, new β -lactam and non- β -lactam inhibitors including the diazobicyclooctanes (DBOs) and the cyclic boronic acid derivatives have emerged and are in development [1,29]. Among several molecules synthesized and under investigations, only avibactam and relebactam among DBOs and vaborbactam among the boronic acid derivative have been approved and are currently clinically applied [14,30]. However, the commercialization of these new inhibitors does not address the need for new compounds able to inactivate the increasing number of KPCs and OXAs-like carbapenemases and the ultra-broad spectrum carbapenemases of class B, including the NDM-1, which can hydrolyse almost all BLAs except aztreonam [31]. Currently, the inhibition of NDM-1 is the main goal pursued by researchers and a variety of NDM-1 inhibitors have been found, including captopril, thiol compounds, Aspergillomarasmine A, new DBO and boric acid derivatives, sulphanilamide compounds, succinic acid derivatives, and a series of natural products. Unfortunately, their physicochemical properties, specificity, and safety to the human body still hamper the approval of their clinical use, and no anti-NDM-1 inhibitor has been marketed until now [31]. The scope of this review was to provide the state of the art concerning the BLEsIs developed so far, including both those already clinically approved and marketed and those at the various stages of development. Originally, to not duplicate the existing reviews concerning this topic, in this work, we have examined BLEsIs by a chemistry approach, with particular attention to their chemical structure. To this end, we have herein reviewed the long-established synthesis adopted to prepare the old BLEsIs, those reported to afford the BLEsIs recently approved, and those lately described to prepare the most relevant molecules yet in development, which have shown potent

inhibiting activity. To make the understanding of the described synthetic procedures easy, for each one, the relative synthetic scheme has been also supplied.

2. β -Lactamase Enzymes (BLEs)

Before delving into the world of BLEs, we felt it was our duty to provide some essential information on the most clinically relevant BLEs. BLEs are produced by both Gram-positive and Gram-negative bacteria to develop resistance to BLAs. Such bacteria include methicillin resistant *Staphylococcus aureus* (MRSA), *Enterobacteriaceae* such as *K. pneumoniae*, *Citrobacter* spp, *Proteus vulgaris*, *Morganella* spp, *Salmonella* spp, *Shigella* spp, *Escherichia coli*, *Haemophilus influenzae*, *Neisseria gonorrhoeae*, as well as by *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, and *Mycobacterium tuberculosis* [22]. Genes encoding BLEs can be either on bacterial chromosomes and are not horizontally transmittable, or on horizontally transmittable plasmids. According to the primary sequence homology and Ambler classification, BLEs have been arranged into four classes, namely A, B, C, and D [32]. BLEs of class A, C, and D belong to the SBLEs, which catalyse the hydrolysis of BLAs via a serine-bound acyl ester intermediate [11]. Such intermediate is formed thanks to a nucleophilic acyl substitution reaction, due to the attaching of the hydroxyl group of the serine present in the active site of the enzyme to the carbonyl group of the β -lactam ring of BLAs, thus triggering its opening. Next, the nucleophilic attack by a water molecule cleaves the covalent bond between the enzyme and the carbonyl group of the β -lactam ring, generating a carboxylic group. This allows the degraded β -lactam antibiotic to diffuse away, thus freeing up the enzyme to process other β -lactam molecules. Additionally, a decarboxylation can occur, thus leading to the complete and irreversible inactivation of BLAs (Scheme 1).



Scheme 1. Inactivation of BLAs through the hydrolytic action of SBLEs.

Differently, the class B enzymes belong to the MBLEs, which require zinc for activity. Particularly, MBLEs cleave β -lactams by a mechanism like that of metalloproteases, which are protease enzymes whose catalytic mechanism involves a metal. No covalent intermediate is formed, and this is the reason of the ineffectiveness of the currently clinically approved BLEs, which work binding BLEs covalently. Regarding this, the spread of bacterial strains expressing MBLEs, such as the NDM-1, has engendered considerable concerns [33].

The metal ion zinc (Zn^{2+}), which catalyses the hydrolytic action of MBLEs, is coordinated to the protein via three ligands, which can vary with histidine, glutamate, aspartate, lysine, and arginine. The fourth coordination position is taken up by a labile hydrolysing water molecule, which is activated by the divalent cation. Treatment with chelating agents,

such as EDTA, leads to the complete inactivation of the enzyme, due to its chelator capability that removes zinc.

The three-dimensional (3D) crystal structures of several class A, C, and D BLEs and those of bacterial transpeptidases, including PBPs, are similar, thus suggesting a common evolutionary origin. On the contrary, the 3D structures of several class B enzymes have a lack of similarity with those of the SBLEs and transpeptidases, thus indicating a different and independent evolutionary origin.

Collectively, more than 400 different types of BLEs have been reported. Table 2 provides a list of the most clinically relevant enzymes belonging to the class A, B, C, and D.

Table 2. The most clinically relevant BLEs grouped according to Ambler classification, the producer bacteria, and the hydrolysed or resistant BLAs.

BLEs	Ambler Class	Subclass	Producer Bacteria	Susceptible BLAs	Not Susceptible BLAs	
SBLEs ESSBLEs	A	KPCs * [34]	<i>K. pneumoniae</i> <i>Enterobacter</i> spp., <i>Salmonella</i> spp. <i>P. aeruginosa</i> <i>A. baumannii</i>	carbapenems	N.R.	
		GESs [35–37]	<i>P. aeruginosa</i>	N.R.	N.R.	
		CTX-Ms ** [35–38]	<i>S. entericaseroovar typhimurium</i> <i>E. coli</i> <i>Enterobacteriaceae</i> .	cefotaxime ceftazidime ceftriaxone cefepime	N.R.	
		SHVs [35–37]	<i>Enterobacteriaceae</i> <i>P. aeruginosa</i>	aztreonam 3rd cefotaxime 3rd ceftazidime	cefazolin cefepime	
	D (CHDLs §)	OXAs * [39,40]	<i>Enterobacteriaceae</i> <i>P. aeruginosa</i> <i>Acinetobacter</i> supp.	ampicillin cephalothin oxacillin cloxacillin carbapenems cefotaxime cefepime	N.R.	
		C [35–37,41]	ACTs ^a	<i>Enterobacteriaceae</i>	cephalothin cefazolin cefepime penicillin derivatives cefotaxime ceftazidime ceftriaxone	N.R.
			DHAs ^a			
CMYs ^a						
ADCs ^a						

Table 2. Cont.

BLEs	Ambler Class	Subclass	Producer Bacteria	Susceptible BLAs	Not Susceptible BLAs
MBLEs ¹	B [42–47]	B1 ^{*,2}	<i>P. aeruginosa</i> <i>A. baumannii</i> <i>Enterobacteriaceae</i> ,	penicillin cephalosporins carbapenems	
		B2 ^{*,3}		carbapenems	penicillin cephalosporins
		B3 ^{*,2}		penicillin cephalosporins carbapenems	

ESSBLEs = extended spectrum serine β -lactamases enzymes confer to producing bacteria resistance to expanded-spectrum (extended-spectrum) cephalosporins; KPCs = *K. pneumoniae* carbapenemases; GESs = Guiana extended-spectrum β -lactamases; CTX-Ms = extended-spectrum β -lactamases active on cefotazime (cefotazimase-Munnich); SHVs = Sulfhydryl variable; TEM = from the Patient's name: Temoneira; OXAs = oxacillinase group of β -lactamases able to hydrolyse oxacillin; ^a AmpC cephalosporinases that cannot be inhibited by clavulanate, some of which are capable to hydrolyse carbapenems; * carbapenemases; ** ESSBLs unable to hydrolyse carbapenems; [§] CHDLs = carbapenem-hydrolysing class D β -lactamases recently discovered which are capable of hydrolysing carbapenems; ¹ inactivated by metal chelators such as EDTA; ² inhibits penicillins, cephalosporins, and carbapenems; ³ inhibits only carbapenems.

TEMs are the most common class A BLEs, whose genes are present in plasmids of Gram-negative bacteria. At least 140 BLEs of TEM-type have been currently reported. The ESSBLEs of class A named SHVs, of which 60 varieties are known, are spread worldwide, but are predominant in Europe and in the United States [35–37].

More than 40 class A ESSBLEs of CTX-M-type are known, including CTX-M-14, CTX-M-3, and CTX-M-2, and are particularly spread in South America, prevailing over TEM and SHV during the first decade of the 21st century [35–38].

Class A carbapenemases of KPC family are encoded in plasmids and are the most widely spread enzymes hydrolysing carbapenems distributed worldwide [34].

Several *Enterobacteriaceae* and a few other bacteria expressing the chromosomal AmpC gene produce the class C AmpC ESSBLEs, which can inactivate several penicillin derivatives and cephalosporins and many combinations BLEs/BLAs. Additionally, in *E. coli*, *K. pneumoniae*, and *P. mirabilis*, which are missing the chromosomal AmpC gene or poorly express it, a transmissible plasmid encoding gene for AmpC enzymes can appear [35–37].

Antibiotics of the carbapenems family are usually effective to treat infections by bacteria producing AmpC ESSBLEs, but carbapenem resistance has been observed in some pathogens due to other phenomena associated with the overexpression of the AmpC gene, such as the reduction of outer membrane porins, or the enhancement of the BLAs efflux by an increased activation of efflux pumps [35–37].

Generally, other class C BLEs do not provide resistance to carbapenems, but five enzymes belonging to this group recently identified and named ACT-1, DHA-1, CMY-2, CMY-10, and ADC-68 have been shown to be capable of hydrolysing carbapenems [39].

The OXA-type BLEs belonging to the class D, except for OXA-18, are carried on plasmids. Bacteria producing OXAs are resistant to several BLAs, including carbapenems, but except for OXA-48-producers *Enterobacteriaceae*, OXAs producing bacteria go back to being susceptible if clavulanic acid is associated. Interestingly, although the discovery of class D OXA-type carbapenemases (also named carbapenem hydrolysing class D lactamase (CHDLs) dates to many years ago, their rapid spread is very recent [1,40].

Other enzymes, such as *Pseudomonas* extended resistance (PERs), Vietnam extended-spectrum (VEBs), *Serratia fonticola* (SFO-1), Tlahuicas (Indian tribe) (TLA-1), Brazilian ESSBLEs (BES-1), GESs Belgium ESSBLEs (BEL-1), and TLA-2, which has 51% amino-acid identity with TLA-1, are uncommon plasmids-mediated ESSBLEs, which are produced mainly by *P. aeruginosa* [35–37].

The MBLEs of class B are enzymes mediated by plasmids that, although initially found only in poorly pathogenic environmental bacterial species, are now found in several clinically relevant strains of Gram-negative bacteria [42]. According to similarities in the sequences, MBLEs are grouped into subclasses B1, B2, and B3 [43]. Among MBLEs, IMPs, VIMs, GIMs, SIMs, SPMs, and NDMs represent the most common families [42]. The first transferable MBLE was IMP-1, which was found in an isolate of *P. aeruginosa* in Japan in 1988, and now is detected worldwide into the *Enterobacteriaceae*. Indeed, IMPs were reported in Europe (1997), Canada, and Brazil. VIM-1 (Verona integron-encoded metallo- β -lactamase-1), comprising 14 varieties of enzymes now globally distributed, was found in Verona, Italy, in 1997. While rare in *Enterobacteriaceae*, VIM-type ESSBLEs are commonly produced by *P. aeruginosa* and *P. putida*.

SPM-1 (Sao Paulo MBLE), GIM-1 (German imipenemase) and SIM-1 (Seoul imipenemase) were isolated in Sao Paulo (Brazil) in 1997, in Germany (2002), and in Korea (2003), respectively.

Worryingly, bacteria carrying the NDM-1 resistance gene, which was first isolated in India and has now spread worldwide, are considered a new type of “superbug” able to inactivate almost all BLAs, except aztreonam, thus leading to the development of multidrug-resistant bacteria [44].

Particularly, NDM-1 belongs to the B1 subclass of MBLEs of group B and is composed of a single polypeptide chain of 27.5 KDa. Three loop regions, L3, L7, and L10, form the main part of the active site, which allocates at the bottom two positively charged zinc ions (Zn1/Zn2) having catalytic activity [45–47]. The broad-spectrum activity of NDM-1 is due to the presence of a wide and shallow substrate-binding capsule cavity, which is capable of easily accepting different types of BLAs.

3. Old and Novel β -Lactamase Enzymes Inhibitors (BLEsIs)

Except for some molecules recently developed, BLEsIs are compounds without intrinsic antibacterial effects. Administered in association with BLAs no longer effective because they were hydrolyzed by BLEs, their main objective is to protect the associated antibiotics. Particularly, by binding the active site of the BLEs, BLEsIs prevent their hydrolytic action on BLAs, which recover their original activity [48,49].

Currently, the available armamentarium of inhibitors and of associations BLAs/BLEsIs clinically approved and already used in therapy to treat infections by bacteria producing BLEs is very poor, and their spectrum of action is still too limited. Presently, the available marketed BLEsIs are only six, of which tazobactam, clavulanate, and sulbactam are effective mainly against SBLEs and ESSBLEs of class A, not including carbapenemases, and avibactam is also active on class A carbapenemases of KPC group, AmpC enzymes of class C, and OXA-48 carbapenemases of class D, while relebactam and vaborbactam possess a spectrum of action slightly narrower than that of avibactam since they are not active against OXA-like enzymes [1,30]. No already approved BLEsI is active against MBLEs. Mainly, BLEsIs are classified as β -lactam inhibitors having a β -lactam core, and as non- β -lactam inhibitors having either a DBO core or other types of non- β -lactam cores. Among the clinically approved inhibitors, clavulanic acid or clavulanate, sulbactam, tazobactam, and tebipenem pivoxil (approved and marketed only in Japan) are β -lactam inhibitors, avibactam and relebactam are non- β -lactam inhibitors having a DBO core, and vaborbactam is a non- β -lactam inhibitor having a cyclic boronic acid core [50–53]. Interestingly, while β -lactam inhibitors form an irreversible bond with the active site of BLEs, avibactam and the other non- β -lactam inhibitors not containing a β -lactam ring bind reversibly to BLEs [48,54].

In addition to the currently marketed BLEsIs, several new molecules that are not yet on the market, which are still at preclinical studies or even at very early-stages of development, have been synthesised. Table 3 report the structures of the most relevant BLEsIs already clinically approved and marketed, as well as those of bioactive molecules not yet approved and only at preclinical trials or even at the in vitro experimentation step. Considering the

most clinically relevant BLEs, the spectrum of action of BLEsIs reported in Table 3 has been also evidenced in an eye-catching way.

Table 3. Long-standing or recently approved BLEsIs, molecules still at preclinical and clinical trials, and molecules still at the early stages of experimentation.





































BLEsIs	Chemical Structure	Not Carbapenemases SBLEs			Carbapenemases SBLEs				MBLEs			
		Class A	Class C	Class D	Class A	Class D		Class C	Class B			
		GES CTX-M SHV TEM	AmpC	N.R.	KPC	OXA23	OXA 24/40	OXA-48	N.R.	NDM	VIM	IMP
Clavulanic Acid (CA) ^{*,1} [55,56]												
Sulbactam ^{*,1} [57–59]												
Tazobactam ^{*,1} [60–62]												

Table 3. Cont.




































BLEsIs	Chemical Structure	Not Carbapenemases SBLEs			Carbapenemases SBLEs			MBLEs				
		Class A	Class C	Class D	Class A	Class D	Class C	Class B				
		GES CTX-M SHV TEM	AmpC	N.R.	KPC	OXA23	OXA 24/40	OXA-48	N.R.	NDM	VIM	IMP
Tebipenem pivoxil ^{*,1,2} [63]									N.R.			
Enmetazobactam ^{*,§} [64–67]												
6-methylidene penems ^{*,1,§} [68]												

Table 3. Cont.













































BLEsIs	Chemical Structure	Not Carbapenemases SBLEs			Carbapenemases SBLEs			MBLEs				
		Class A	Class C	Class D	Class A	Class D	Class C	Class B				
		GES CTX-M SHV TEM	AmpC	N.R.	KPC	OXA23	OXA 24/40	OXA-48	N.R.	NDM	VIM	IMP
LN-1-255 *,\$ [30,69–71]									N.R.			
Avibactam §,** [1,16,62,72–78]									N.R.			
Relebactam §,** [15,62,79–81]									N.R.			
Zidebactam §§§,3,\$ [22,62,82–85]									N.R.			

Table 3. Cont.











































BLEIs	Chemical Structure	Not Carbapenemases SBLEs			Carbapenemases SBLEs			MBLEs				
		Class A	Class C	Class D	Class A	Class D	Class C	Class B				
		GES CTX-M SHV TEM	AmpC	N.R.	KPC	OXA23	OXA 24/40	OXA-48	N.R.	NDM	VIM	IMP
Durlobactam §,3,4,5 [62,86–89]									N.R.			
Nacubactam §,3,5 [62,90–94]								N.R.	N.R.			
ETX-1317 §,3,5 [62,95–99]						N.R.	N.R.		N.R.			
WCK-5153 §,3,5 [100,101]												

Table 3. Cont.










































BLEsIs	Chemical Structure	Not Carbapenemases SBLEs			Carbapenemases SBLEs			MBLEs				
		Class A	Class C	Class D	Class A	Class D	Class C	Class B				
		GES CTX-M SHV TEM	AmpC	N.R.	KPC	OXA23	OXA 24/40	OXA-48	N.R.	NDM	VIM	IMP
WCK-4234 §,3,§ [101–103]									N.R.			
ANT-3310 §,3,§ [104,105]									N.R.			
GT-055 §,3,§ [62,106–108]						N.R.	N.R.	N.R.	N.R.			
Vaborbactam #,**, [62,109–114]									N.R.			

Table 3. Cont.











































BLEsIs	Chemical Structure	Not Carbapenemases SBLEs				Carbapenemases SBLEs				MBLEs		
		Class A	Class C	Class D	Class A	Class D		Class C	Class B			
		GES CTX-M SHV TEM	AmpC	N.R.	KPC	OXA23	OXA 24/40	OXA-48	N.R.	NDM	VIM	IMP
Taniborbactam #,3,\$,## [115–118]						N.R.	N.R.		N.R.			
Ledaborbactam etzadroxil (VNRX-7145 #,3,\$,##) (Prodrug of VNRX-5236, blue structure) [62,119–121]									N.R.			
Xeruborbactam(QPX- 7728) #,3,\$,## [62,122–126]							N.R.		N.R.			

Table 3. Cont.

BLEsIs	Chemical Structure	Not Carbapenemases SBLEs			Carbapenemases SBLEs			MBLEs				
		Class A	Class C	Class D	Class A	Class D	Class C	Class B				
		GES CTX-M SHV TEM	AmpC	N.R.	KPC	OXA23	OXA 24/40	OXA-48	N.R.	NDM	VIM	IMP
ANT-2681 ***,3,\$,## [62,127–130]												

* Long standing established β -lactam inhibitors; \$ not yet marketed; ** recently developed; *** 3-(sulphonamide)thiazole-4-carboxylic acid non- β -lactam inhibitor; \$ di-azo-bicyclo-octane non- β -lactam inhibitors; # non- β -lactam inhibitors derived from boronic acid; \$\$ bicyclo-acyl hydrazide non- β -lactam inhibitor; ## NDM inhibitors; ¹ no inhibition of carbapenemases; ² already marketed only in Japan for paediatric patients (Orapenem[®]) inhibits class A blaC BLE produced by *Mycobacterium tuberculosis*; ³ under investigation in preclinical/clinical trials; ⁴ administered with sulbactam 1/1 in clinical trials; N.R. = not reported.

4. BLAs/BLEsIs Combinations Currently Available on the Market and Clinically Applied

The following Table 4 summarizes the clinically approved BLAs/BLEsIs combinations currently marketed in Europe and USA, with the most common brand names, the available dosage forms, as well as the suggested clinical uses and dosage for both adult patients and paediatric ones.

Table 4. BLAs/BLEs combinations currently marketed in Europe and USA with the most common brand names, the available dosage forms, the suggested clinical uses, and posology.

Brand Name	Composition §	Dosage Form	Type of Infection	Posology
Augmentin® [131]	Amoxicillin/K clavulanate 7/1 875 mg/125 mg	Film Coated Tablets (adults)		1 tablet 2/3 a day
	Amoxicillin/K clavulanate 7/1 875 mg/125 mg	Powder for oral suspension in sachets (adults/children ≥ 40 kg)		1 sachet 2/3 times a day
	Amoxicillin/K clavulanate 7/1 400 mg/57 mg	Powder for oral suspension in sachets (children)	Diabetic foot cIAIs, cUTIs, LRTIs	25/3.6 mg to 45/6.4 mg/Kg day given in two doses.
	Amoxicillin/K clavulanate 7/1 400 mg/57 mg/5 mL	Powder for oral suspension in sachets (children)	Pulmonary infections Brain abscesses Prophylaxis after surgery	25/3.6 mg to 45/6.4 mg/Kg day given in two doses with measuring spoon or syringe
		Powder for solution for injection/infusion (adults/children ≥ 40 kg)	Acute otitis Sinusitis Skin infections	1000 mg/200 mg every 8 h
	Amoxicillin/K clavulanate 5/1 1000 mg/200 mg	Powder for solution for injection/infusion (children < 40 kg)	Gynecologic infections Septicemia Bone and joint infections	Children ≥ 3 months 25 mg/5 mg/kg every 8 h
		Powder for solution for infusion (adults/children ≥ 40 kg)	Endometritis Peritonitis	Children < 3 months or < 4 kg 25 mg/5 mg/kg every 12 h
	Amoxicillin/K clavulanate 10/1 2000 mg/200 mg	Powder for solution for injection/infusion (children < 40 kg)		1000 mg/100 mg every 8/12 h
			Children ≥ 3 months 50 mg/5 mg/kg every 8 h	
			Children < 3 months or < 4 kg 50 mg/5 mg/kg every 12 h	

Table 4. Cont.

Brand Name	Composition §	Dosage Form	Type of Infection	Posology
Timentin® [132]	(Na) ₂ Ticarcillin/K clavulanate 30/1 30 mg/mL/1 mg/mL	Injection Powder for solution (adults ≥ 60 kg)	Systemic infections, cUTIs	3.1 g Timentin every 4/6 h
			gynecologic infections *	Moderate infections 200 mg/kg/day every 6 h Severe infections 300 mg/kg/day in divided doses every 4 h.
		Injection Powder for solution (children ≥ 3 month)	Aspiration Pneumonia Bacteremia cUTIs, cIAIs, VAP, HAP Appendicitis Bone infection	Mild/moderate infections 200 mg/kg/day divided doses every 6 h Severe infections 300 mg/kg/day divided doses every 4 h
Clavucar [133]	(Na) ₂ Ticarcillin/K clavulanate 5/1 1000 mg/200 mg	Intramuscular Injection (IMI) (adults)	Aspiration Pneumonia Bacteremia cUTIs, cIAIs, VAP, HAP Appendicitis Bone infection Gynecologic infections	1 bottle (1.2 g) 2–3 times a day.
	(Na) ₂ Ticarcillin/K clavulanate 15/1 3000 mg/200 mg	Intravenous Infusion (IVI) (adults)		1 bottle (3.2 g) every 8 h
Zosyn® [134]	Piperacillin/Na tazobactam 8/1 Zosyn 2.25 g/50 mL, 3.375 g/50 mL, 4.5 g/100 mL	Frozen iso-osmotic sterile non-pyrogenic premixed solution for IVI	Cellulitis Diabetic foot LRTIs cIAIs, cUTIs, HAP, VAP Gynaecologic Skin infections Appendicitis Postpartum endometritis Stomach infections Severe uterine infections	Adults 3.375 g Zosyn every six hours totaling 13.5 g a day 12.0 g piperacillin 1.5 g tazobactam
	Piperacillin/Na tazobactam 8/1 Zosyn 2.25, 3.375, 4.5 g single dose vials	Powder/lyophilized for solution for IVI		Pediatric patients ≥ 9 months < 40 kg 112.5 mg/Kg Zosyn every 8 h Pediatric patients 2–9 months 90 mg/Kg Zosyn every 8 h
Zerbaxa [135]	Ceftalozane sulfate 1000 g Na tazobactam 500 g 2/1	Powder for concentrate for solution for IVI	HAP, VAP, cIAIs Acute pyelonephritis	1 bottle (1.5 g) every 8 h Not for individuals < 18 years

Table 4. Cont.

Brand Name	Composition §	Dosage Form	Type of Infection	Posology
Unasyn® [136]	Na Ampicillin/Na Sulbactam (2/1)/1.6 mL 500 mg/250 mg	Powder and solvent for solution for injection		Adults 3–12 g Unasyn/a day Every 6, 8, 12 h
	Na Ampicillin/Na Sulbactam (2/1)/3.2 mL 1000 mg/500 mg	Powder and solvent for solution for IMI	VAP, HAP, cUTIs, cIAIs Lower respiratory tract Gynecological Obstetric	
	Na Ampicillin/Na Sulbactam (2/1)/3.2 mL 1000 mg/500 mg	Powder and solvent for solution for IVI	Acute epiglottitis Periorbital cellulitis Diabetic foot	Children 150 mg/kg/die every 6–8 h
	Na Ampicillin/Na Sulbactam (2/1) 1000 mg/500 mg	Powder for solution for IMI	Skin and soft tissue Gonorrhoea Otitis media	Neonates 75 mg/kg/die every 12 h
Sultamicillin®, ¹ [137]	Bounded ampicillin and sulbactam	Tablets (375, 750 mg)		Adults 375–750 mg/day Children < 30 Kg 25–50 mg/kg/day in 2 doses
Sulperazon® [138]	Na cefoperazone/Na Sulbactam 1/1 1000 mg/1000 mg	Injection Powder for injection	Upper/LRTIs cUTIs, cIAIs Sepsis Meningitis Skin infections Bone and joint infections Endometritis Gonorrhoea	Adults 2–4 mg Sulperazon/day divided into 2 doses Children 40–80 mg/kg/day in 2–4 doses New-borns Max 80 mg/kg/day in 2 doses
Recarbrio™ [139]	Imipenem/Na cilastatin/relebactam 2/2/1 500 mg/500 mg/250 mg	Power for solution IVI	cUTIs, cIAIs, HAP, VAP	1.25 g Recarbrio every 6 h Not for individuals < 18 years

Table 4. Cont.

Brand Name	Composition §	Dosage Form	Type of Infection	Posology
Zavicefta® [141]		Power for solution for IVI (2.5 g)		3–6 months 50 mg/Kg Avycaz every 8 h
Avycaz® [140]	Ceftazidime/avibactam 4/1 2000 mg/500 mg	Vials for IVI (2.5 g)	cIAIs, HAP, VAP cUTIs (pyelonephritis)	>18 years old 2.5 g Avycaz every 8 h 3 months–2 years old 62.5 mg/Kg Avycaz every 8 h 2–18 years old 62.5 mg/Kg Avycaz every 8 h
Vabomere® [142]	Meropenem/vaborbactam 1/1 1000 mg/1000 mg	Power for solution for IVI (2.0 g)	cUTIs, cIAIs, HAP, VAP Acute pyelonephritis	>18 years old 4g Vabomere every 8 h

§ The reported weights refer to the free form or to the anhydrous forms of drugs; LRTIs = lower respiratory tract infections; cUTIs = complicate urinary tract infections; cIAIs = complicated intraabdominal tract infections; VAP = ventilator acquired pneumonia; HAP = hospital acquired pneumonia; Na = sodium; * for patients weighing less than 60 kg, the recommended dosage is 200 to 300 mg/kg/day, based on ticarcillin content, given in divided doses every 4 to 6 h; ¹ Chemical name: hydroxymethyl (2S,5R,6R)-6-[([®])-(2-amino-2-phenylacetamido)]-3,3-dimethyl-7-oxo-4-tia-1-azabicyclo [3.2.0] heptane-2-carboxylate, (2S,5R)-3,3-dimethyl-7-oxo-4-tia-1-azabicyclo [3.2.0] heptane-2-carboxylate (ester), S,S-dioxide (WHO) is a prodrug (ester) of sulbactam and ampicillin.

5. Marketed and Not Marketed BLEs: Guidelines for Their Synthesis


5.1. β -Lactams

Generally, the synthetic procedures reported to prepare β -Lactams BLEs start from the naturally occurring (+)-6-aminopenicillanic acid (6-APA). Clavulanic acid is instead prepared biosynthetically, as reported in the subsequent Section, while the synthesis of tebipenem pivoxil has been reported starting from a commercially available 6-APA derivative.

5.1.1. Already Clinically Approved β -Lactams BLEs

Biosynthesis of Clavulanic Acid

Clavulanic acid (CA) was first identified from *Streptomyces clavuligerus* and later from other *Streptomyces* species. Structurally, clavulanic acid is characterized by a bicyclic nucleus comprising a four-membered β -lactam ring fused to a five-membered oxazolidine ring. While resembling penicillin, CA has an oxygen atom in place of a sulfur one in the five-membered cycle, does not possess an acylamino substituent, and has an exo- β -hydroxy ethylidene group attached at C-2. Nowadays, CA is produced by the biosynthetic pathway in Scheme 2 [143].




Scheme 2. Biosynthesis of CA (C₈H₉NO₅, MW: 199.16), IUPAC name: (2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo [3.2.0] heptane-2-carboxylic acid.

While arginine and ornithine were proposed to be possible precursors providing the nitrogen atom to obtain CA, in 1993 it was demonstrated that arginine is a more direct precursor than ornithine. Additionally, it was assessed that the β -lactam ring of CA derives from glyceralehyde-3-phosphate, and that carboxyethyl arginine synthase (CEAS), having cofactors Mg²⁺ and thiamine diphosphate (ThDP) present in the active site, is the enzyme responsible for combining these two precursors, providing the N²-carboxyethyl-

arginine. β -lactam synthetase (BLS) catalyzes the second step of the pathway converting the N^2 -(2-carboxyethyl) arginine to deoxy-guanidino-proclavaminic acid, thereby generating the monocyclic β -lactam ring. The catalytic reaction of BLS proceeds by adenylation of the N^2 -(2-carboxyethyl) arginine β -carboxylate followed by cyclization via an oxo-anion intermediate in the presence of ATP and Mg^{2+} . Two other enzymes, namely clavamate synthase (CAS) and proclavamate amidino hydrolase (PAH), catalyze the subsequent reactions to generate the bicyclic intermediate, namely clavaminic acid. Particularly, deoxy guanidino proclavaminic acid is first hydroxylated by CAS to give guanidino proclavaminic acid, which under the action of PAH that removes the arginine-derived guanidino group, is converted to proclavaminic acid. Then, CAS contributes again to the next two reactions, initially catalyzing the formation of the first bicyclic intermediate through oxidative ring closure of proclavaminic acid to give dihydroclavaminic acid, and then forming clavaminic acid by desaturation. Then, N-glycyl-clavaminic acid synthetase (GCAS), which is a member of the ATP-grasp fold superfamily, catalyzes the conversion of clavaminic acid to N-glycyl-clavaminic acid in an ATP-dependent manner. Although the mechanism by which N-glycyl-clavaminic acid is converted to clavaldehyde is still not clear, it is assumed that a double epimerization and an oxidative deamination reaction should occur to ultimately yield clavaldehyde. Clavaldehyde, otherwise 3R,5R-clavulanate-9-aldehyde, is an unstable α , β -unsaturated aldehyde with β -lactamase inhibitory activity, which finally undergoes reduction to give clavulanic acid in an NADPH-dependent reaction catalyzed without degradation of the bicyclic β -lactam ring by clavulanic acid dehydrogenase (CAD).

Synthesis of Sulbactam

According to the patent by Chen et al. [144], sulbactam acid was prepared according to Scheme 3. Briefly, bromine, a diluted sulfuric acid solution, and solid sodium nitrite were added to an aqueous solution of 6-APA **1** to perform diazotization, achieving the intermediate **2** and bromination to obtain intermediate **3**. Then, an aqueous solution of potassium permanganate and diluted sulfuric acid was added dropwise to the intermediate **3** to perform an oxidation reaction and obtain the sulphone derivative **4**, which was treated with strontium powder and diluted sulfuric acid to perform its reductive debromination and obtain sulbactam in a yield of 90%.




Scheme 3. Synthesis of sulbactam from 6-APA ($C_8H_{11}NO_5S$, MW = 233.2), IUPAC name: (2S,5R)-3,3-dimethyl-4,4,7-trioxo-4 λ 6-thia-1-azabicyclo [3.2.0] heptane-2-carboxylic acid.

Synthesis of Tazobactam

Different synthetic procedures have been reported in the literature to prepare tazobactam starting from 6-APA. According to the patent by Shiyong reported in Scheme 4 [145], tazobactam was obtained performing first the deamination of 6-APA under the action of H_3PO_2 and $NaNO_2/HCl$ to obtain **1**, followed by the oxidation of the sulfur atom of **1** into


sulfoxide group using ceric triflate/hydrogen peroxide [$\text{Ce}(\text{OTf})_4/\text{H}_2\text{O}_2$] as an oxidant system to obtain compound **2**.



Scheme 4. Synthesis of tazobactam from 6-APA ($\text{C}_{10}\text{H}_{12}\text{N}_4\text{O}_5\text{S}$, MW = 300.3), IUPAC name: 3S-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo [3.2.0] heptan-2S-carboxylic acid 4,4-dioxide.

Compound **2** was treated with trifluoroacetic anhydride (TFAA) and was refluxed at $95\text{--}105\text{ }^\circ\text{C}$ under reduced pressure to obtain the acylated compound **3**, which reacted with hydrazine hydrate to give the reduced compound **4**. Next, using triethylamine (Et_3N) as an acid binding agent, **4** was treated with methane sulfonyl chloride to obtain the sulfonated compound **5**. By condensing **5** and triazole in the presence of Et_3N to achieve **6** and oxidating **6** with hydrogen peroxide and acetic anhydride (Ac_2O) in the presence of sodium polyphosphate to obtain a sulfone group, tazobactam was obtained as free acid.

According to the authors, the advantages of this procedure consist of simple operation steps and of low-cost raw materials being easy to obtain. Additionally, the reaction steps are short, and the obtained intermediate products have high purity. The final product of tazobactam acid obtained as white solid powder showed a purity of more than 99.5% and the high total molar yield makes this procedure suitable for industrial production. Very recently, Shuhao et al. have reported a combination of continuous flow and batch experiments for the synthesis of tazobactam, which was prepared as described in Scheme 5 [146]. The continuous flow method has not only greatly reduced the reaction time, but also significantly improved procedure safety and increased the yield.




Scheme 5. Synthesis of tazobactam according to the method proposed by Shuhao et al.

Briefly, 6-APA and potassium bromide were added to an aqueous solution of sulfuric acid and dichloromethane (DCM) at 0°C , and the mixture was added with an aqueous solution of sodium nitrite. After the reaction, the organic phase containing the 6-bromo derivative of 6-APA (6-BrPA), was washed with saturated brine, treated with 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC), diphenylmethanol,

and dimethyl amino pyridine (DMAP) to realize the protection of the carboxylic group, and the product was directly treated without separation with 50% hydrogen peroxide, acetic acid, sulfuric acid, and ethylenediaminetetraacetic acid (EDTA). The 20% peroxyacetic acid formed oxidized the sulfur atom of the protected 6-BrPA to sulfoxide group. The subsequent treatment with zinc and ammonium acetate (NH₄Ac) provided the 6,6-dihydropenicillin-3- α -carboxylic acid as white solid, which was transformed in the 3-methyl-[2-oxo-4-(2-benzothiazole di-thio)-1-azacyclobutyl]-3-butenic acid by treatment with 2-mercaptobenzothiazole in toluene, refluxing for 80 min. The obtained compound was then reacted with CuBr₂ to obtain the 2- β -bromomethyl-2- α -methylpenicillin-3- α -carboxylic acid diphenyl methyl ester which was transformed in β -(1,2,3-triazol-1-yl) methyl-2- α -methyl-6,6-dihydropenicillin-3- α -carboxylic acid diphenyl methyl ester by reacting it with 1,2,3-triazole in acetone/water. The tazobactam precursor, namely 2- β -(1,2,3-triazol-1-yl) methyl-2- α -methyl-6,6-dihydropenicillin-3- α -carboxylic acid diphenyl methyl 1,1-dioxide, was obtained in DCM and acetic acid (AcOH) under treatment with potassium permanganate. Tazobactam was finally obtained, deprotecting the previous compound dissolved in *m*-cresol with 15% hydrochloric acid for 3 h, and then filtered.

Synthesis of Tebipenem Pivoxil

Initially researched and developed by Pfizer Inc. (New York City, NY, USA), tebipenem pivoxil developed by Japanese Mingzhi company obtained Japan's approval and went on Japan's market in April 2009. Tebipenem pivoxil is the orally available prodrug of tebipenem, which is hydrolyzed *in vivo* by esterase enzymes and, even if only in Japan, it is the only orally administrable carbapenem marketed. While acting as BLAs by binding PBPs, and inhibiting the synthesis of bacteria cell wall, tebipenem also works as inhibitor of BLEs produced by *M. tuberculosis*. The improved synthesis of tebipenem pivoxil was described by Peng and co-workers and has been herein shown in Scheme 6 [147].



Scheme 6. Synthesis of tebipenem pivoxil (C₂₂H₃₁N₃O₆S₂, MW: 497.6), IUPAC name: 2,2-dimethylpropanoyloxymethyl (4R,5S,6S)-3-[1-(4,5-dihydro-1,3-thiazol-2-yl) azetidino-3-yl] sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo [3.2.0] hept-2-ene-2-carboxylate.


Briefly, tebipenem pivoxil was synthesized from commercially available materials as (4-nitrophenyl)methyl (4R,5R,6S)-3-[(diphenoxyphosphinyloxy]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo [3.2.0] hept-2-ene-2-carboxylate **1** and 3-mercapto-1-(1,3-thiazolin-2-yl) azetidine **2** via a substitution reaction in presence of ethyl-di-isopropyl-amine [EtN(iPr)₂]

in acetonitrile (MeCN), which afforded compound 3. Its subsequent hydrogenation under H_2 pressure in butanol (BuOH) to remove the p-nitro-benzyl protecting group followed by esterification with 2,2-dimethyl-propionic acid iodo-methyl ester using benzyl triethylammonium chloride (TEBAC) afforded tebipenem pivoxil with a total yield of 56.7%. This process was prone to operating in high yield and it provided a basis for a pilot scale production.

5.1.2. Not Yet Clinically Approved β -Lactam BLEsIs

Synthesis of Enmetazobactam

Since it is structurally like tazobactam, except for the presence of an additional methyl group in the triazole ring, enmetazobactam can be prepared directly upon methylation of tazobactam. Three procedures have been reported in literature to perform the methylation of the triazole ring [148–150]. According to the procedure described in the patent by Faini et al. [150], enmetazobactam was prepared from tazobactam via silylation/esterification, with N,O-bis(trimethylsilyl)acetamide in DCM followed by quaternization via N-alkylation of the obtained intermediate with methyl triflate and subsequent desilylation with sodium 2-ethylhexanoate in EtOH (Scheme 7).




Scheme 7. Synthesis of enmetazobactam, formerly AAI101 ($C_{11}H_{14}N_4O_5S$, MW = 314.3), IUPAC name: (2S,3S,5R)-3-methyl-3-[(3-methyltriazol-3-ium-1-yl)-methyl]-4,4,7-trioxo-4 λ 6-thia-1-azabicyclo [3.2.0] heptane-2-carboxylate.

Similar procedures that have been slightly modified have been reported by Senthil Kumar et al. and by Palanisamy et al. [148,149]. Notably, in a first step, a tazobactam suspension in acetone at 25–30 °C was added slowly with N,O-bis(silyl)acetamide and then with methyl iodide in place of methyl triflate to obtain the quaternization of the triazole ring. Then, the afforded solid product was, in a second step, treated with sodium thiosulfate in water, and after the due purification procedures using a solution of Amberlite LA-2 resin, DCM washings, and activated carbon, enmetazobactam was obtained upon lyophilization.

General Procedure to Synthesize 6-Methylidene-penem Carboxylic Acid Sodium Salts

Various 6-methylidene-penem carboxylic acid sodium salts were achieved according to Scheme 8 [151,152].




Scheme 8. Synthetic route to prepare 6-methylidene-penam carboxylic acid sodium salts starting from 6-APA.

Briefly, 6-APA was converted to 6(S)-bromo penicillanic acid **1** by treatment with NaNO_2 in the presence of HBr . Then, the esterification of the di-cyclohexylamine salt of **1** with p-methoxybenzyl bromide, followed by oxidation with m-chloro-perbenzoic acid (MCPBA), afforded the sulfoxide **2**. Sulfoxide **2** was then heated to reflux in toluene with 2-mercaptobenzothiazole to firstly achieve the sulfenic acid which, reacting with the mercaptan, provided the disulfide **3**. Compound **3** was then transformed by a base-catalyzed double bond isomerization to the conjugated ester disulfide **4**, which was in turn transformed in the formyl-thio-derivative **5** by reductive formylation. By ozonolysis of **5**, the oxalamide **6** was obtained, which underwent cyclisation to provide the crystalline p-methoxybenzyl (SR,6S)-6-bromopenem-3-carboxylate **7**, by heating a toluene solution of **6** at 95°C for 30 min in the presence of excess trimethyl phosphite [$\text{P}(\text{MeO})_3$]. Subsequently, involving a Lewis acid (anhydrous MgBr_2), an aldol condensation reaction was performed between several selected aldehydes and **7** in the presence of Et_3N as the base. The resulting bromohydrins **8** were trapped in the form of their respective acetylated derivatives **9**.

Then, for performing the reductive elimination procedure to introduce a Z-double bond between the C6 and C7 on the obtained acetoxy bromohydrins, a neutral procedure was devised using freshly prepared activated zinc and 0.5 M (pH 6.5) phosphate buffer (PBS) at room temperature in acetonitrile–THF (1:2). The resultant crude products were purified by Diaion HP-21 resin (80 mL, Mitsubishi Kasei Co. Ltd.) column chromatography. Finally, following Lewis's acid-mediated deprotections of the ester compounds and treatments with Na_2HPO_4 aqueous solutions, the correspondent sodium salts were obtained.

Synthesis of LN-1-255

Among other penicillin sulfones, which structurally incorporate both a 6-position alkylidene substituent and a 2'- β -substituent, LN-1-255 has been synthesized by Buynak et al. according to Scheme 9 [153].



Scheme 9. Synthetic route to prepare LN-1-255 from 6-APA ($C_{22}H_{19}N_2NaO_9S$, MW = 510.4), IUPAC name: (2*S*,3*R*,5*R*,6*Z*)-4-thia-1-azabicyclo [3.2.0] heptane-2-carboxylic acid, 3-[[[(3,4-dihydroxyphenyl) acetyl] oxy] methyl]-3-methyl-7-oxo-6-(2-pyridinylmethylene)-4,4-dioxide, monosodium salt.

Firstly, 6-APA was treated with EDC, diphenylmethanol, and DMAP to protect the carboxylic group and obtain compound **1**, which was transformed in α -diazo- β -lactam by means of 2-nitropropane in trifluoro acetic acid (TFA) and then into the α -oxo- β -lactam **2** using catalytic amounts of rhodium (II) in the presence of the extremely mild oxygen donor, propylene oxide. The obtained α -oxo- β -lactam **2** underwent a Wittig reaction using the triphenyl-pyridin-2-yl-methyl-phosphonium chloride and $NaNH_2$. The oxidation of the 6-methylidene pyridine derivative **3** with MCPBA afforded the corresponding sulfoxide, which was heated to reflux in toluene with 2-mercaptobenzothiazole, obtaining the corresponding disulfide. The disulfide was reacted with 3,4-di-tert-butoxy-phenyl-acetic acid and silver acetate, and after removal of the t-butyl protecting groups by TFA treatment and the benzyl protecting group by catalytic hydrogenation, LN-1-255 was achieved. By treatment with Na_2HPO_4 aqueous solutions, the corresponding sodium salt was achieved.

5.2. Non- β -Lactam DBO BLEsIs


Non- β -lactam BLEsIs named DBOs consist of molecules which do not possess a β -lactam ring but have a five-membered DBO ring and an amide group, which is the responsibility of the interaction with the active-site of SBLEs by a carbamylation reaction. While the β -lactam BLEsIs interact irreversibly with the enzymes, DBOs do not. Particularly, DBOs bind reversibly to the enzyme in the active site and undergo the opening of the DBO

ring forming carbamate derivatives, following a de-acylation process to regenerate the original compounds, which can inactivate new enzymes.

5.2.1. Clinically Approved DBO BLEsIs

Synthesis of Avibactam

The first patents describing the synthesis of avibactam were published in 2002 (international version) and in 2003 (US version). The original syntheses of avibactam do not provide details on the absolute configuration of the molecule. Subsequently, the synthesis of avibactam starting from chiral derivatives was described. Chiral piperidines, L-glutamic acid, and L-pyrroglutamic acid were considered as starting materials and Boc-benzyl-L-glutamate was used to optimize the synthetic process [154]. Recently, Laure Peilleron and Kevin Cariou have reported the synthesis of avibactam starting from a commercially available chiral oxo-pyrrolidine (Scheme 10) [155] (Novexel).




Scheme 10. Synthesis of avibactam (MF: $\text{C}_7\text{H}_{11}\text{N}_3\text{O}_6\text{S}$, MW = 265.25), IUPAC name: [(2S,5R)-2-carbamoyl-7-oxo-1,6-diazabicyclo [3.2.1] octan-6-yl] hydrogen sulphate.

Briefly, Novexel chemists started the synthesis of avibactam from commercially available enantiopure 2-pyrrolidone (γ -lactam), having Boc and benzyl protecting groups. First, the γ -lactam was subjected to Corey–Chaykovsky-type reaction conditions in a mixture dimethyl sulfoxide/tetrahydrofuran (DMSO/THF) as solvent, and the addition of a sulfonium ylide yielded the zwitterionic enolate **1**. The reaction of **1** with lithium hydroxide (LiOH) and methane sulfonic acid (MsOH) gave an intermediate chloro-ketone onto which O-benzylhydroxylamine (BnONH₂) was condensed to furnish the E/Z oxime **2**. The cyclization to piperidine **3** was followed by acidic treatment to remove the Boc protecting group and by the reduction of oxime to hydroxylamine derivative that was isolated as its oxalate salt **4** (75/25 trans/cis isomers). The bicyclic core was generated by treatment with tri-phosgene to form the ureic derivative **5**. A rigorously controlled ester saponification with LiOH allowed to hydrolyze selectively the trans derivative, thus solely obtaining

the corresponding trans carboxylic acid, which was converted to the primary amide **6** by treatment with pivaloyl chloride followed by ammonia. Then, after debenzoylation by hydrogenolysis, the sulfate group was introduced, and avibactam was isolated first as tetrabutylammonium salt and then as sodium salt. Subsequently, the transformation of the starting material into piperidine was optimized using potassium tert-butoxide ($t\text{-BuO}^- \text{K}^+$) in place of sodium hydride, performing the chlorination and the formation of the oxime in a one-pot fashion, and purifying only the final piperidine. Since only the trans isomer of piperidine **3** was isolated, only the R isomer of **4** was obtained after reduction, therefore the selective saponification step could be avoided, and the amide derivative was directly obtained from **4**. Subsequently, a selective fluorenyl-methyl-oxycarbonyl (Fmoc) protection of the amine was necessary before activating the hydroxylamine with carbonyl di-imidazole to give an intermediate which, upon deprotection of the Fmoc group, underwent cyclization in the presence of di-ethylamine to give the bicyclic adduct **7**.

Synthesis of Relebactam

The scale-up synthesis of relebactam has been described in Scheme 11 [156].




Scheme 11. Synthesis of relebactam ($\text{C}_{12}\text{H}_{20}\text{N}_4\text{O}_6\text{S}$, MW = 348.4, IUPAC name: [(2*S*,5*R*)-7-oxo-2-(piperidin-4-ylcarbamoyl)-1,6-diazabicyclo [3.2.1] octan-6-yl] hydrogen sulphate.

The synthesis comprised the sulfonylation of 5-hydroxypiperidine-2-carboxylic acid with 2-nitrobenzene sulfonyl chloride ($o\text{-NsCl}$) followed by an intramolecular esterification which provided bridged ring compound **2**. Next, a ring-opening reaction involving the

Boc-protected amino-piperidine followed by treatment with *o*-NsCl and DMAP generated the corresponding arene-sulphonate **3**. Compound **3** was then treated with *N*-benzyloxybenzylsulfamide to give the corresponding product of substitution, namely **4**. Treatment of **4** with thioglycolic acid gave **5**, which was the key intermediate of this synthesis. By the treatment of **5** with tri-phosgene in the presence of *N,N*-diisopropylethylamine (DIPEA), cyclization occurred, generating a chiral bridged ring intermediate **6**. Then, **6** was treated with catalytic Pd/Al₂O₃ under hydrogen gas in THF to remove the benzyl protecting group and obtain **7**, which was in turn sulfated using tetrabutylammonium bis-sulphate as a sulfate radical source and 2-picoline as a base in THF. After sulfate formation and *N,O*-bis(trimethylsilyl)trifluoroacetamide (BSTFA) and trimethylsilyl iodide (TMSI) mediated *N*-Boc deprotection, treatment with acetic acid promoted acidic precipitation of relebactam.

5.2.2. Not Yet Clinically Approved DBO BLEsIs Synthesis of Zidebactam

In addition to various patents, the synthesis of zidebactam has been described by Papp-Wallace and co-workers as reported in Scheme 12 [101].



Scheme 12. Synthesis of zidebactam (C₁₃H₂₁N₅O₇S, MW = 391.4), IUPAC name: [(2*S*,5*R*)-7-oxo-2-[[[(3*R*)-piperidine-3-carbonyl] amino] carbamoyl]-1,6-diazabicyclo [3.2.1] octan-6-yl] hydrogen sulphate.

Briefly, starting from *trans*-6-benzyloxy-7-oxo-1,6-diazabicyclo [3.2.1] octane-2-carboxylic acid sodium salt, which is an intermediate of the synthesis of avibactam previously described, compound **1** was obtained using *N,N*-dimethyl formamide (DMF), EDC hydrochloride, butyl alcohol, and (*R*)-*N*-tert-butoxycarbonyl-piperidin-3-carboxylic acid hydrazide. Then, once **1** was obtained as a white solid, it was dissolved in methanol and treated with 10% palladium on carbon under pressure of hydrogen to provide **2** as a pale pink solid, which was used for the next reaction immediately. Therefore, **2** was treated with pyridine sulfur trioxide complex, in pyridine in the presence of a 0.5 N aqueous potassium dihydrogen phosphate solution and tetrabutylammonium sulphate to provide **3**


as a yellowish solid, in quantitative yield. Finally, zidebactam was obtained as free sulfonic acid by treating **3** with TFA in DCM to remove the Boc protecting group.

Synthesis of WCK 5153

WCK5153 ($C_{12}H_{19}N_5O_7S$, MW = 377.1), IUPAC name, (2*S*,5*R*)-7-oxo-2-(2-((*S*)-pyrrolidine-3-carbonyl)hydrazine-1-carbonyl)-1,6-diazabicyclo [3.2.1] octan-6-yl hydrogen sulfate, was synthesized as zidebactam using (*R*)-*N*-tert-butoxycarbonyl-pyrrolidin-3-carboxylic acid hydrazide in place of (*R*)-*N*-tert-butoxycarbonyl-piperidin-3-carboxylic acid hydrazide according to Papp-Wallace et al. [101].

Synthesis of WCK-4234

Scheme 13 represents the synthesis of WCK-4234 [101].




Scheme 13. Synthesis of WCK-4234 ($C_7H_8N_3NaO_5S$, MW = 269.3), IUPAC name: sodium (2*S*,5*R*)-2-cyano-7-oxo-1,6-diazabicyclo [3.2.1] octan-6-yl sulfate.

The trans-6-benzyloxy-7-oxo-1,6-diaza-bicyclo [3.2.1] octane-2-carboxylic acid sodium salt was converted into the anhydride **1** by treating the sodium salt with triethylamine hydrochloride (TEA) in DCM and reacting the resulting compound with pivaloyl chloride in the presence of TEA at 0–5 °C. Compound **1** was reacted as such with a 25% aqueous solution of ammonia in water at –20 °C to obtain the amide **2** as an off-white solid after workup and purification. The amide was dehydrated with trifluoroacetic anhydride (TFAA) in the presence of TEA in DCM to obtain the cyano derivative **3**, which was debenzoylated with 10% Pd/C in a 1/1 mixture of DMF/DCM under hydrogen atmosphere to obtain the hydroxyl compound **4**. This compound was then immediately sulfated with the DMF:SO₃ complex to obtain the sulfate, which was isolated as its tetrabutylammonium salt **5** by reacting with tetrabutylammonium acetate. The tetrabutylammonium salt was converted to WCK-4234 in the form of sodium salt by passing **5** through a column filled with Indion 225 sodium resin.

Synthesis of ETX-1317 and of Its Orally Administrable Prodrug ETX-0282

The gram-scale synthesis of ETX-0282 and ETX-1317 was reported by Durand-Réville and colleagues and has been presented in Scheme 14 [97].



Scheme 14. Part A: Synthesis of the ethyl bromo-fluoroacetates I and II used to prepare compounds 10 and ETX-0282 of Part B. Part B: Synthesis of ETX-1317 and of its orally administrable prodrug ETX-0282. ETX-1317 ($\text{C}_{10}\text{H}_{12}\text{FN}_3\text{O}_5$, MW = 295.2), IUPAC name: (2R)-2-(((2S,5R)-2-carbamoyl-3-methyl-7-oxo-1,6-diazabicyclo [3.2.1] oct-3-en-6-yl)-oxy)-2-fluoroacetic acid. ETX-0282 ($\text{C}_{13}\text{H}_{18}\text{FN}_3\text{O}_5$, MW = 315.3), IUPAC name: isopropyl (R)-2-(((1R,2R,5R)-2-carbamoyl-4-methyl-7-oxo-1,6-diazabicyclo [3.2.1] oct-3-en-6-yl)-oxy)-2-fluoroacetate.


The chiral isopropyl and ethyl bromo-fluoroacetates I and II were first prepared in three steps from racemic ethyl bromo-fluoroacetate by saponification with NaOH, followed by chiral salt resolution using (S)-1-phenylethylamine. The chiral salt was then

re-esterified using isopropanol or ethanol to give the (R)-isopropyl and the desired ethyl bromo-fluoro-acetate. The key intermediate of the synthesis of ETX0282 and ETX1317 was the hydroxyurea **III**, which was prepared in 10 steps from commercially available materials. Briefly, ethyl 2-oxoacetate and (S)-2-methylpropane-2-sulfinamide were condensed to afford the chiral imine **1**. An aza-Diels–Alder reaction with isoprene provided compound **2**, which underwent deprotection to remove the tert-butyl sulfinyl group to afford **3**, subsequently Boc protected, to give compound **4**. The saponification of the ester followed by amide coupling using 1,1'-carbonyldiimidazole (CDI) and ammonium acetate afforded compound **5**. Among the many strategies developed to install the hydroxylamine functionality in a regio- and stereo-selective manner, the reaction of alkene **5** with N-Boc-hydroxylamine in the presence of oxygen or air gave the desired compound **6** in a single step and in 40% yield. Compound **6** was then protected with a tert-butyl-silyl (TBS) group using TBS chloride (TBSCl) to afford **7**, which was Boc deprotected using zinc bromide obtaining compound **8**. Cyclization of the diamine **8** with tri-phosgene provided the corresponding cyclic urea **9**, which was TBS deprotected with HF-pyridine (HFPy) to give the key intermediate **III**. By alkylation of **III** with **I** or **II**, in the presence of 1,8-diazabicyclo [5.4.0] undec-7-ene, (DBU), ETX-0282 and compound **10** were obtained, respectively, while ETX1317 was prepared in 63% yield from **10** by saponification with lithium hydroxide.

Synthesis of Durlobactam

Chemically, durlobactam is [(2S,5R)-2-carbamoyl-3-methyl-7-oxo-1,6-diazabicyclo [3.2.1] oct-3-en-6-yl] hydrogen sulfate which can be prepared from the key intermediate hydroxyurea 6-hydroxy-3-methyl-7-oxo-1,6-diaza-bicyclo [3.2.1] oct-3-ene-2-carboxylic acid amide **I**, which is the structural isomer of **III** prepared to synthesize ETX-1317 [101]. Then, according to Scheme 15, compound **1** obtained in the synthesis of **III** (Scheme 14) was reacted with penta-1,3-diene in place of isoprene, and, by an aza-Diels–Alder reaction, compound **2** was obtained.

Compound **2** underwent deprotection of the tert-butyl sulfinyl group to afford **3**, subsequently Boc protected, to give compound **4**. The saponification of the ester followed by amide coupling using ammonium acetate afforded compound **5**. The reaction of alkene **5** with N-Boc-hydroxylamine in the presence of oxygen or air gave the desired compound **6** in a single step. Compound **6** was then protected with TBS group, using TBSCl to afford **7**, which was Boc deprotected using zinc bromide obtaining compound **8**. Cyclization of the diamine **8** with tri-phosgene provided the corresponding cyclic urea **9**, which was TBS deprotected with HFPy to give the key intermediate **I**. This compound was then immediately sulfated with the DMF:SO₃ complex to obtain the sulfate, which was isolated as its tetrabutylammonium salt **10** by reacting with tetrabutylammonium acetate. The tetrabutylammonium salt was converted to durlobactam in the form of sodium salt by passing **10** through a column filled with Indion 225 sodium resin.




Scheme 15. Synthesis of durlobactam ($\text{C}_8\text{H}_{11}\text{N}_3\text{O}_6\text{S}$, MW = 277.36, IUPAC name, [(2S,5R)-2-carbamoyl-3-methyl-7-oxo-1,6-diazabicyclo [3.2.1] oct-3-en-6-yl] hydrogen sulphate.

Synthesis of ANT-3310

The syntheses of various DBOs have been recently reported by Davies and colleagues, starting from the commercially available 5-benzyloxyamino-piperidine-2-carboxylic acid ethyl ester—oxalate salt [127]. With the same procedure, it is also possible to start using the compound 4 obtained during the synthesis of avibactam, as reported in the Scheme 16.


Briefly, the benzyl protected diamine oxalate salt 4, prepared as shown in Scheme 10, was converted to the free base 1 using potassium hydrogen carbonate, which was cyclized to the bicyclic urea 2 with tri-phosgene. The subsequent saponification of compound 2 using LiOH provided the key intermediate 3. The following decarboxylation and radical treatment of 3 with Selectfluor in the presence of AgNO_3 gave the fluoro derivative 4a, which was transformed in compound 5 by hydrogenolysis to remove benzyl protecting group. Compound 5 was then submitted to the usual chemistry sequence described previously to achieve other DBOs for obtaining ANT-3310.



Scheme 16. Synthesis of ANT-3310 ($C_6H_9FN_2O_5S$, MW = 240.2), IUPAC name, (2R,5R)-2-fluoro-7-oxo-1,6-diazabicyclo [3.2.1] octan-6-yl hydrogen sulphate.

Synthesis of Nacubactam

Performing a procedure described in a patent by Maiti and co-workers, nacubactam can be prepared according to Scheme 17 [157].



Scheme 17. Synthesis of nacubactam ($C_8H_{16}N_4O_7S$, MW = 324.3), IUPAC name, [(2S,5R)-2-(2-aminoethoxycarbonyl)-7-oxo-1,6-diazabicyclo [3.2.1] octan-6-yl] hydrogen sulphate.

Briefly, starting from the key intermediate 3, obtained during the previous synthesis, and using the commercially available 2-(aminoethoxy) carbamic acid tert-butyl ester 1 in the presence of benzotriazolol and EDC hydrochloride as condensing agents, 4-DMAP as catalyst, and DCM as solvent, the compound 2 was obtained. Then, compound 2 was submitted to the usual chemistry sequence described previously, including debenzoylation and treatment with pyridineSO₃ in pyridine, to achieve 4. The subsequent removal of Boc protecting group with TFA provided nacubactam in the form of trifluoroacetate salt.

Synthesis of GT-055

According to our knowledge, up to today, no synthetic procedure has been reported in literature to prepare GT-055 (also referred to as LCB18-055), responding to the IUPAC name: sulfuric acid mono-[2-(5,5-bis-aminomethyl-4,5-dihydro-isoxazol-3-yl)-7-oxo-1,6-diaza-bicyclo [3.2.1] oct-6-yl] ester; trifluoro-acetate salt ($C_{13}H_{20}F_3N_5O_8S$, MW = 463.4).


5.3. Non- β -Lactam Boronic Acid Derivatives

Non- β -lactam boronic acid derivatives, developed to afford non-acylating BLEs, are cyclic derivatives of boronic acid, which can react very rapidly with BLEs, forming stable enzyme-inhibitor complexes.

5.3.1. Clinically Approved Boronic Acid Derivative

Synthesis of Vaborbactam

The synthesis of various cyclic boronates, including vaborbactam, has been reported by Scott and co-workers, as shown in Scheme 18 [110].



Scheme 18. Synthesis of vaborbactam (formerly RPX-7009) ($C_{12}H_{16}BNO_5S$, MW = 297), IUPAC name, 2-[(3*R*,6*S*)-2-hydroxy-3-[(2-thiophen-2-ylacetyl)-amino]-oxaborinan-6-yl]-acetic acid.


Briefly, vaborbactam was prepared in a six-step procedure in an overall yield of about 30% starting from the enantiopure β -hydroxy ester **1**, in turn prepared by lipase-mediated kinetic resolution of the corresponding racemate. Particularly, compound **1** was protected as silyl ether with *tert*-butyl-dimethylsilyl chloride (TBDSCl) and imidazole, achieving compound **2**. Its regioselective hydroboration catalyzed by $[Ir(COD)Cl]_2$ gave the pinacol boronate **3**, which was converted to the more stable pinanediol boronate **4**. Its stereoselective chloromethylation following Matteson's protocol at $-95\text{ }^\circ\text{C}$, using butyl lithium (*n*-BuLi) and DCM afforded the (*S*)-chloro homologue **5** as an 85:15 mixture of diastereomers. Then, the displacement of the chlorine group with lithium hexamethyl disilazide

(LiHMDS) followed by in situ acylation with the thiophen-2-yl-acetic acid gave the acyl amido boronate **6**. The acidic removal of all protecting groups afforded vaborbactam.

5.3.2. Not Yet Clinically Approved Boronic Acid Derivatives


Synthesis of Taniborbactam

According to Liu et al., taniborbactam was prepared as shown in Scheme 19 [158].



Scheme 19. Synthesis of taniborbactam (formerly VNRX-5133), ($C_{19}H_{28}BN_3O_5$, MW = 389.3), IU-PAC name: (3R)-3-[[2-[4-(2-aminoethylamino)-cyclohexyl]-acetyl]-amino]-2-hydroxy-3,4-dihydro-1,2-benzoxaborinane-8-carboxylic acid.

Starting from the commercially available 3-borono-2-methoxybenzoic acid **1** and using isobutylene, followed by the esterification of the boronic acid with (+)-pinanediol, compound **2** was prepared. Following Matteson's protocol, the aryl boronate **2** was reacted with chloromethyl lithium at $-100\text{ }^{\circ}\text{C}$ to provide **3** in excellent yield. A second homologation reaction with the anion derived from DCM ($-100\text{ }^{\circ}\text{C}$) selectively provided the (S)- α -chloro-boronate **4**. The stereospecific displacement of the chlorine atom of **4** with lithium bis(trimethylsilyl)amide at $-20\text{ }^{\circ}\text{C}$ afforded the intermediate α -silyl amino boronate **5**, which was coupled in situ using 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU) and N-methyl morpholine (NMM) to the requisite carboxylic acid **1**, in turn prepared as reported in Scheme 20. The resultant amide **6** was deprotected and cyclized by treatment with BCl_3 (1 M in DCM) at $-78\text{ }^{\circ}\text{C}$ to afford the crude boronate **7**, which was purified by reverse-phase high-performance liquid chromatography (HPLC) and then lyophilized to dryness.




Scheme 20. Synthesis of ((4-[tert-Butoxycarbonyl-(2-tert-butoxycarbonylamino-ethyl)-amino]-cyclohexyl)-acetic acid (I).

The carboxylic acid I was prepared starting from the commercially available (4-tert-butoxycarbonylamino-cyclohexyl)-acetic acid **1**, by its alkylation with benzyl bromide to give the ester derivative **2**. The removal of the Boc protective group afforded the amine **3** as HCl salt, which was converted to the intermediate **4** via reductive amination. The protection of the secondary amine and the removal of the benzyl group provided I in a 30% yield over five steps.

Synthesis of VNRX-7145

VNRX-7145, also known as ledaborbactam etzadroxil, which is the orally bioavailable prodrug of ledarbobactam (VNRX-5236), was prepared as shown in Scheme 21 using the intermediate **4** of the previous synthesis as a starting material [120].




Scheme 21. Synthesis of VNRX-7145, also known as ledaborbactam etzadroxil, which is the orally bioavailable prodrug of ledarbobactam (VNRX-5236). VNRX-7145 (C₁₉ H₂₆ B N O₇, MW 391.2), IUPAC name: 2-hydroxy-3-propionylamino-3,4-dihydro-2H-1-oxa-2-bora-naphthalene-8-carboxylic acid 2-ethyl-butylloxymethyl ester. VNRX-5236 (C₁₂ H₁₄ B N O₅, MW 263.1), IUPAC name: 2-hydroxy-3-propionylamino-3,4-dihydro-2H-1-oxa-2-bora-naphthalene-8-carboxylic acid.

Particularly, compound **4**, isolated from two consecutive homologation reactions following Matteson's protocol, was treated with lithium bis(trimethylsilyl)amide (LHMDS) at $-20\text{ }^{\circ}\text{C}$ to afford the desired stereoisomer intermediate **1**. The α -silylaminoboronate intermediate **1** was treated in situ with HATU and NMM and coupled with the propionic acid to achieve compound **2**. Then, **2** was treated with TFA in DCM or 4 N HCl in dioxane to provide acid **3**. Reaction of **3** with sodium carbonate, sodium iodide, and chloromethyl etzadroxilate in DMF afforded ester **4a**. Finally, the pinanediol and methyl ether were selectively removed by treatment with aluminium chloride in DCM to provide the desired compound VNRX-7145.

Synthesis of Xeruborbactam

The synthesis of xeruborbactam has been recently reported by Hecker and colleagues, as shown in Scheme 22 [159].



Scheme 22. Synthesis of xeruborbactam (formerly QPX7728), ($\text{C}_{10}\text{H}_8\text{BFO}_4$, MW = 221.98), IUPAC name: 5-fluoro-2-hydroxy-1,1a,2,7b-tetrahydro-3-oxa-2-bora-cyclopropa[a]naphthalene-4-carboxylic acid.

Briefly, the commercially available 2-bromo-5-fluorophenol **1** was converted to the Boc-protected derivative **2** using di-tert-butyl decarbonate (Boc_2O) and DMAP.


Subsequently, compound **2** was treated with lithium di-isopropyl-amide (LDA) to achieve deprotonation and then with di-tert-butyl decarbonate to obtain the intermediate **3**. The two protecting groups were replaced with a single acetone in compound **4**, which was obtained treating **3** with TFA and acetone. Compound **4** was subjected to a Heck reaction using palladium acetate and chloro-[tri(o-tolyl) phosphine] [2-(2'-amino-1,1'-biphenyl)] palladium (II) ($\text{P}(\text{o-tolyl})_3$) to introduce the acrylate side chain, giving **5**. Bromination of **5** followed by decarboxylative elimination afforded cis-vinyl bromide **6**, which underwent palladium-mediated borylation with the bis[(+)-pinanediolato] di-boron affording the cis-vinyl boronate **7**. Compound **7** was subjected to palladium-catalyzed cyclopropanation with diazomethane to afford **8** as a mixture of two diastereomers, which were separated by HPLC. The subsequent hydrolysis of the acetone with NaOH and of the pinanediol protecting group with TFA in the presence of triethyl silane (TES) and B-tert-butyl boronic acid [$t\text{-BuB}(\text{OH})_2$] afforded xeruborbactam.

5.4. Non- β -Lactam Thiazolyl Acid Derivatives

Non- β -lactam thiazolyl acid derivatives are small molecules that are structurally different from the other novel inhibitors previously described. Among them, ANT-2681 contains a thiazole carboxylate derivative consisting of a 3,5-difluorobenzosulfonamide nucleus linked to a 4-thiazol-carbamide in the position 5 of the heterocycle with an ureidoguanidine residue in position 4.

Synthesis of the Not Yet Approved ANT-2681

ANT-2681 was prepared by Davies and his group according to Scheme 23 [160].



Scheme 23. Synthesis of ANT-2681 ANT-2681 (C₁₂H₁₂F₂N₈O₄S₂, MW = 434.4), IU-PAC name: 5-((4-(2-Carbamimidoylhydrazine-1-carboxamido)-3,5-difluorophenyl) sulphonamide) thiazole-4-carboxamide.

The commercially available methoxybenzyl isothiocyanate **1** was treated with a solution of tert-butyl iso-cyanoacetate previously added to a suspension of potassium tert-butoxide in dry tetrahydrofuran, achieving compound **2** as a pale-yellow solid. Subsequently, **2** was added to a suspension of NaH and then treated with a solution of 4-bromo-3,5-difluoro-benzenesulfonyl chloride in THF achieving **3** as a pale-yellow solid again. By treating a mixture of **3**, Xantphos, tris (dibenzylidene acetone) dipalladium (0) [Pd₂(dba)₃] and K₃PO₄ with a saturated solution of NH₃ in dioxane was afforded **4**, which was transformed in the unstable nitrophenyl carbamate **5** by treatment with (4-nitrophenyl) chloroformate in toluene at room temperature. The nitrophenyl carbamate was used in the next step without further purification. Therefore, a solution of compound **5** in THF was reacted with DIPEA affording **6** as a pale-yellow solid, which was converted in the intermediate **7** using HCl in Et₂O. **7** was obtained as an off-white solid, which was immediately used without purification. The treatment of **7** with DIPEA and N,N'-bis(tert-butoxy carbonyl)-1H-pyrazole-1-carboxamide in DMF afforded **8**, which was converted to the desired product ANT-2681 using TFA at room temperature. With this step, ANT-2681 was isolated as zwitterion, which was purified by preparative HPLC. Subsequently, ANT-2681 was isolated as sodium salt by treatment with 0.05N aqueous NaOH at room temperature in deionized water.

6. Conclusions and Authors Considerations

By now, it is established that the defensive strategy of bacteria against β -lactam antibiotics (BLAs) mainly consists of producing β -lactamase enzymes (BLEs), while the current approach of scientists to rehabilitate antibiotics that are no longer functioning and counteracting infections that are increasingly difficult to treat consists of developing β -lactamases inhibitors (BLEsIs). In the context of this work, after having briefly provided the basic information about the most clinically relevant BLAs and BLEs, we have originally examined BLEsIs by a chemical approach. Particularly, we have herein reviewed both the already clinically approved BLEsIs, and those yet under early stages, preclinical, and clinical investigations developed so far, reporting the long-established synthetic procedures, as well as those recently optimized and still to be optimized present in literature.

Unfortunately, along with our investigation to produce this work, it has been evidenced that, while both the number of BLEs-producing bacteria and that of BLEs themselves are rapidly and constantly evolving, the number of BLEsIs clinically approved and available for therapeutic uses is evolving very slowly. The genes encoding for bacterial BLEs are easily transmitted between bacteria, especially if linked to plasmids, thus continuously increasing the number of pathogens producing BLEs. Additionally, these enzymes change continuously, giving rise to an increasing number of new variants of BLEs with an expanding broader spectrum of action and the capability of inactivating even the last generation associations BLAs/BLIs.

The alarming scenario is that of an unequal struggle between a small number of inhibitors and an immense and increasing number of different types of BLEs, progressively potent, which make the researchers' effort to create substances capable of covering their entire spectrum of action almost utopic. Nowadays, among the BLEsIs researched, developed, and in development, the clinically approved ones are only 27%, while most of them are still in the preclinical or clinical trials (63%), or even at very early stages of development (10%).

In Europe and the USA, only six are the products currently on the market, and among these, no compound is active on class B MBLEs, including NDM-1, which is able to hydrolyze all available antibiotics except for aztreonam. The long-established β -lactam inhibitors are inactive on carbapenemases, which can inactivate the most resistant carbapenems of last generation. Only three compounds recently developed, two belonging to the DBOs compounds and one making part of the boronic acid derivatives, inhibit class A carbapenemases (KPC), while only the DBO avibactam is active on class D OXA-like carbapenemases.

Promisingly, higher percentages of associations BLAs/BLEs are active on class D OXA-like carbapenemases (56.4%) and on class A carbapenemases of KPC family (74.5%), if not yet approved BLEs are also considered. Particularly, although the percentages of compounds active against most class D carbapenemases and above all against carbapenemases of class B is still low, almost all the new not clinically applied BLEs in development are capable to inhibit KPCs, and more than 50% work well against OXA-48.

This situation highlights that an increasing effort to synthesize a progressively higher number of differently structured molecules also capable of inhibiting the most recent and potent variants of BLEs produced by the most clinically relevant bacteria is necessary. To this end, a successful approach consists of considering molecules or chemical nuclei already known for being active as BLEs as templates and making structural changes to improve their potency and spectrum of activity. Therefore, we think that having provided with this review detailed information concerning the most accredited synthetic procedures to prepare the key molecules of each structural category to date investigated as BLEs, this could be of great use for pharmaceutical chemists operating in the sector.

Author Contributions: Conceptualization, S.A. methodology, software, validation, formal analysis, investigation, data curation, visualization, supervision, and project administration, S.A. Writing—original draft preparation, S.A. Writing—review and editing, S.A. and G.Z. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data is contained within the article.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Tooke, C.L.; Hinchliffe, P.; Bragginton, E.C.; Colenso, C.K.; Hvievonen, V.H.A.; Takebayeshi, Y.; Spencer, J. β -Lactamases and β -Lactamase Inhibitors in the 21st Century. *J. Mol. Biol.* **2019**, *431*, 3472–3500. [[CrossRef](#)] [[PubMed](#)]
2. Bush, K. Past and Present Perspectives on β -Lactamases. *Antimicrob. Agents Chemother.* **2018**, *62*, e01076-18. [[CrossRef](#)] [[PubMed](#)]
3. List of β -lactam Antibiotics. From Wikipedia, the Free Encyclopedia. Available online: https://en.wikipedia.org/wiki/List_of_%CE%B2-lactam_antibiotics (accessed on 8 February 2022).
4. Sauvage, E.; Kerff, F.; Terrak, M.; Ayala, J.A.; Charlier, P. The Penicillin-Binding Proteins: Structure and Role in Peptidoglycan Biosynthesis. *FEMS Microbiol. Rev.* **2008**, *32*, 234–258. [[CrossRef](#)] [[PubMed](#)]
5. Palzkill, T. Metallo- β -Lactamase Structure and Function. *Ann. N. Y. Acad. Sci.* **2013**, *1277*, 91–104. [[CrossRef](#)]
6. Neu, H.C. Aztreonam Activity, Pharmacology, and Clinical Uses. *Am. J. Med.* **1990**, *88*, S2–S6. [[CrossRef](#)]
7. Sykes, R.B.; Bonner, D.P. Aztreonam: The First Monobactam. *Am. J. Med.* **1985**, *78*, 2–10. [[CrossRef](#)]
8. Papp-Wallace, K.M.; Endimiani, A.; Taracila, M.A.; Bonomo, R.A. Carbapenems: Past, Present, and Future. *Antimicrob. Agents Chemother.* **2011**, *55*, 4943–4960. [[CrossRef](#)]
9. Babic, M.; Hujer, A.M.; Bonomo, R.A. What's New in Antibiotic Resistance? Focus on Beta-Lactamases. *Drug Resist. Updates* **2006**, *9*, 142–156. [[CrossRef](#)]
10. Bush, K.; Fisher, J.F. Epidemiological Expansion, Structural Studies, and Clinical Challenges of New β -Lactamases from Gram-Negative Bacteria. *Annu. Rev. Microbiol.* **2011**, *65*, 455–478. [[CrossRef](#)]
11. Ghuysen, J.-M. SERINE β -LACTAMASES AND PENICILLIN-BINDING PROTEINS. *Annu. Rev. Microbiol.* **1991**, *45*, 37–67. [[CrossRef](#)]
12. Crowder, M.W.; Spencer, J.; Vila, A.J. Metallo- β -Lactamases: Novel Weaponry for Antibiotic Resistance in Bacteria. *Acc. Chem. Res.* **2006**, *39*, 721–728. [[CrossRef](#)] [[PubMed](#)]
13. Wang, Z.; Fast, W.; Valentine, A.M.; Benkovic, S.J. Metallo- β -Lactamase: Structure and Mechanism. *Curr. Opin. Chem. Biol.* **1999**, *3*, 614–622. [[CrossRef](#)]
14. Tehrani, K.H.M.E.; Martin, N.I. β -Lactam/ β -Lactamase Inhibitor Combinations: An Update. *Med. Chem. Commun.* **2018**, *9*, 1439–1456. [[CrossRef](#)]
15. Karaiskos, I.; Galani, I.; Papoutsaki, V.; Galani, L.; Giamarellou, H. Carbapenemase Producing Klebsiella Pneumoniae: Implication on Future Therapeutic Strategies. *Expert Rev. Anti-Infect. Ther.* **2021**, *20*, 53–69. [[CrossRef](#)] [[PubMed](#)]
16. Khanna, N.R.; Gerriets, V. Beta Lactamase Inhibitors. In *StatPearls*; StatPearls Publishing: Treasure Island, FL, USA, January 2022. Available online: https://www.ncbi.nlm.nih.gov/books/NBK557592/#_NBK557592_pubdet_ (accessed on 8 February 2022).

17. El-Gamal, M.I.; Brahim, I.; Hisham, N.; Aladdin, R.; Mohammed, H.; Bahaeldin, A. Recent Updates of Carbapenem Antibiotics. *Eur. J. Med. Chem.* **2017**, *131*, 185–195. [CrossRef]
18. Maveyraud, L.; Mourey, L.; Kotra, L.P.; Pedelacq, J.-D.; Guillet, V.; Mobashery, S.; Samama, J.-P. Structural Basis for Clinical Longevity of Carbapenem Antibiotics in the Face of Challenge by the Common Class A β -Lactamases from the Antibiotic-Resistant Bacteria. *J. Am. Chem. Soc.* **1998**, *120*, 9748–9752. [CrossRef]
19. Nukaga, M.; Bethel, C.R.; Thomson, J.M.; Hujer, A.M.; Distler, A.; Anderson, V.E.; Knox, J.R.; Bonomo, R.A. Inhibition of Class A Beta-Lactamases by Carbapenems: Crystallographic Observation of Two Conformations of Meropenem in SHV-1. *J. Am. Chem. Soc.* **2008**, *130*, 12656–12662. [CrossRef]
20. Tremblay, L.W.; Fan, F.; Blanchard, J.S. Biochemical and Structural Characterization of Mycobacterium Tuberculosis Beta-Lactamase with the Carbapenems Ertapenem and Doripenem. *Biochemistry* **2010**, *49*, 3766–3773. [CrossRef]
21. Bush, K. Alarming β -Lactamase-Mediated Resistance in Multidrug-Resistant Enterobacteriaceae. *Curr. Opin. Microbiol.* **2010**, *13*, 558–564. [CrossRef]
22. Carcione, D.; Siracusa, C.; Sulejmani, A.; Leoni, V.; Intra, J. Old and New Beta-Lactamase Inhibitors: Molecular Structure, Mechanism of Action, and Clinical Use. *Antibiotics* **2021**, *10*, 995. [CrossRef]
23. Fernández, L.; Hancock, R.E.W. Adaptive and Mutational Resistance: Role of Porins and Efflux Pumps in Drug Resistance. *Clin. Microbiol. Rev.* **2012**, *25*, 661–681. [CrossRef] [PubMed]
24. Li, H.; Luo, Y.-F.; Williams, B.J.; Blackwell, T.S.; Xie, C.-M. Structure and Function of OprD Protein in Pseudomonas Aeruginosa: From Antibiotic Resistance to Novel Therapies. *Int. J. Med. Microbiol.* **2012**, *302*, 63–68. [CrossRef]
25. Ayoub Moubareck, C.; Hammoudi Halat, D. Insights into Acinetobacter Baumannii: A Review of Microbiological, Virulence, and Resistance Traits in a Threatening Nosocomial Pathogen. *Antibiotics* **2020**, *9*, 119. [CrossRef] [PubMed]
26. Moyá, B.; Beceiro, A.; Cabot, G.; Juan, C.; Zamorano, L.; Alberti, S.; Oliver, A. Pan- β -Lactam Resistance Development in Pseudomonas Aeruginosa Clinical Strains: Molecular Mechanisms, Penicillin-Binding Protein Profiles, and Binding Affinities. *Antimicrob. Agents Chemother.* **2012**, *56*, 4771–4778. [CrossRef] [PubMed]
27. Yamachika, S.; Sugihara, C.; Kamai, Y.; Yamashita, M. Correlation between Penicillin-Binding Protein 2 Mutations and Carbapenem Resistance in Escherichia Coli. *J. Med. Microbiol.* **2013**, *62*, 429–436. [CrossRef]
28. World Health Organization. Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics. Available online: <https://www.who.int/news-room/detail/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed> (accessed on 10 February 2022).
29. Olsen, I. New Promising β -Lactamase Inhibitors for Clinical Use. *Eur. J. Clin. Microbiol. Infect. Dis.* **2015**, *34*, 1303–1308. [CrossRef]
30. González-Bello, C.; Rodríguez, D.; Pernas, M.; Rodríguez, Á.; Colchón, E. β -Lactamase Inhibitors To Restore the Efficacy of Antibiotics against Superbugs. *J. Med. Chem.* **2020**, *63*, 1859–1881. [CrossRef]
31. Wang, T.; Xu, K.; Zhao, L.; Tong, R.; Xiong, L.; Shi, J. Recent Research and Development of NDM-1 Inhibitors. *Eur. J. Med. Chem.* **2021**, *223*, 113667. [CrossRef]
32. Ambler, R.P.; Coulson, A.F.; Frère, J.M.; Ghuysen, J.M.; Joris, B.; Forsman, M.; Levesque, R.C.; Tiraby, G.; Waley, S.G. A Standard Numbering Scheme for the Class A β -Lactamases. *Biochem. J.* **1991**, *276*, 269–270. [CrossRef]
33. Rotondo, C.M.; Wright, G.D. Inhibitors of metallo- β -lactamases. *Curr. Opin. Microbiol.* **2017**, *39*, 96–105. [CrossRef]
34. Dahiya, S.; Singla, P.; Chaudhary, U.; Singh, B. Prevalence of Klebsiella pneumoniae Carbapenemase (KPC), Metallo Beta Lactamases and AmpC beta Lactamases in Clinical Isolates of Klebsiella Species. *Int. J. Curr. Microbiol. Appl. Sci.* **2015**, *4*, 170.
35. Sonda, T.; Kumburu, H.; van Zwetselaar, M.; Alifrangis, M.; Lund, O.; Kibiki, G.; Aarestrup, F.M. Meta-Analysis of Proportion Estimates of Extended-Spectrum-Beta-Lactamase-Producing Enterobacteriaceae in East Africa Hospitals. *Antimicrob. Resist. Infect. Control* **2016**, *5*, 18. [CrossRef] [PubMed]
36. Onduru, O.G.; Mkakosya, R.S.; Aboud, S.; Rumisha, S.F. Genetic Determinants of Resistance among ESBL-Producing Enterobacteriaceae in Community and Hospital Settings in East, Central, and Southern Africa: A Systematic Review and Meta-Analysis of Prevalence. *Can. J. Infect. Dis. Med. Microbiol.* **2021**, *2021*, 5153237. [CrossRef]
37. Varela, M.F.; Stephen, J.; Lekshmi, M.; Ojha, M.; Wenzel, N.; Sanford, L.M.; Hernandez, A.J.; Parvathi, A.; Kumar, S.H. Bacterial Resistance to Antimicrobial Agents. *Antibiotics* **2021**, *10*, 593. [CrossRef] [PubMed]
38. Delgado, D.Y.C.; Barrigas, Z.P.T.; Astutillio, S.G.O.; Jaramillo, A.P.A.; Ausili, A. Detection and Molecular Characterization of β -Lactamase Genes in Clinical Isolates of Gram-Negative Bacteria in Southern Ecuador. *Braz. J. Infect. Dis.* **2016**, *20*, 627–630. [CrossRef]
39. Poirel, L.; Naas, T.; Nordmann, P. Diversity, Epidemiology, and Genetics of Class D β -Lactamases. *Antimicrob. Agents Chemother.* **2010**, *54*, 24–38. [CrossRef]
40. Evans, B.A.; Amyes, S.G.B. OXA β -Lactamases. *Clin. Microbiol. Rev.* **2014**, *27*, 241–263. [CrossRef]
41. Jeon, J.H.; Lee, J.H.; Lee, J.J.; Park, K.S.; Karim, A.M.; Lee, C.-R.; Jeong, B.C.; Lee, S.H. Structural Basis for Carbapenem-Hydrolyzing Mechanisms of Carbapenemases Conferring Antibiotic Resistance. *Int. J. Mol. Sci.* **2015**, *16*, 9654–9692. [CrossRef]
42. Boyd, S.E.; Livermore, D.M.; Hooper, D.C.; Hope, W.W. Metallo- β -Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline. *Antimicrob. Agents Chemother.* **2020**, *64*, e00397-20. [CrossRef]
43. Garau, G.; García-Sáez, I.; Bebrone, C.; Anne, C.; Mercuri, P.; Galleni, M.; Frère, J.-M.; Dideberg, O. Update of the Standard Numbering Scheme for Class B Beta-Lactamases. *Antimicrob. Agents Chemother.* **2004**, *48*, 2347–2349. [CrossRef]

44. Poirel, L.; Lagrutta, E.; Taylor, P.; Pham, J.; Nordmann, P. Emergence of Metallo- β -Lactamase NDM-1-Producing Multidrug-Resistant *Escherichia Coli* in Australia. *Antimicrob. Agents Chemother.* **2010**, *54*, 4914–4916. [CrossRef] [PubMed]
45. Guo, Y.; Wang, J.; Niu, G.; Shui, W.; Sun, Y.; Zhou, H.; Zhang, Y.; Yang, C.; Lou, Z.; Rao, Z. A structural view of the antibiotic degradation enzyme NDM-1 from a superbug. *Protein Cell.* **2011**, *2*, 384–394. [CrossRef] [PubMed]
46. Thomas, P.W.; Zheng, M.; Wu, S.; Guo, H.; Liu, D.; Xu, D.; Fast, W. Characterization of Purified New Delhi Metallo- β -Lactamase-1. *Biochemistry* **2011**, *50*, 10102–10113. [CrossRef]
47. Gibb, A.P.; McCallum, A.K. New Delhi Metallo- β -Lactamase 1. *Lancet Infect. Dis.* **2010**, *10*, 751–752. [CrossRef]
48. Drawz, S.M.; Bonomo, R.A. Three Decades of β -Lactamase Inhibitors. *Clin. Microbiol. Rev.* **2010**, *23*, 160–201. [CrossRef] [PubMed]
49. Shahid, M.; Sobia, F.; Singh, A.; Malik, A.; Khan, H.M.; Jonas, D.; Hawkey, P.M. Beta-Lactams and Beta-Lactamase-Inhibitors in Current- or Potential-Clinical Practice: A Comprehensive Update. *Crit. Rev. Microbiol.* **2009**, *35*, 81–108. [CrossRef]
50. Hazra, S.; Xu, H.; Blanchard, J.S. Tebipenem, a New Carbapenem Antibiotic, Is a Slow Substrate That Inhibits the β -Lactamase from *Mycobacterium Tuberculosis*. *Biochemistry* **2014**, *53*, 3671–3678. [CrossRef]
51. FDA Approves New Treatment for Complicated Urinary Tract and Complicated Intra-Abdominal Infections. Food and Drug Administration. 17 July 2019. Available online: <https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-complicated-urinary-tract-and-complicated-intra-abdominal-infections#:~:text=The%20U.S.%20Food%20and%20Drug%20Administration%20has%20approved,tract%20infections%20%28cUTI%29%20and%20complicated%20intra-abdominal%20infections%20%28cIAI%29> (accessed on 10 February 2022).
52. Cilastatin/Imipenem/Relebactam. AdisInsight. Springer International Publishing AG. Retrieved 29 April 2016. Available online: <https://adisinsight.springer.com/drugs/800042881> (accessed on 10 February 2022).
53. FDA Approves New Antibacterial Drug (Press Release). Food and Drug Administration. 29 August 2017. Available online: <https://www.pressreleasepoint.com/fda-approves-new-antibacterial-drug> (accessed on 10 February 2022).
54. Lahiri, S.D.; Mangani, S.; Durand-Reville, T.; Benvenuti, M.; Luca, F.D.; Sanyal, G.; Docquier, J.-D. Structural Insight into Potent Broad-Spectrum Inhibition with Reversible Recyclization Mechanism: Avibactam in Complex with CTX-M-15 and *Pseudomonas Aeruginosa* AmpC β -Lactamases. *Antimicrob. Agents Chemother.* **2013**, *57*, 2496–2505. [CrossRef]
55. Drug Banck Online. Clavulanic Acid: Uses, Interactions, Mechanism of Action. Available online: <https://go.drugbank.com/drugs/DB00766> (accessed on 10 February 2022).
56. Saudagar, P.S.; Survase, S.A.; Singhal, R.S. Clavulanic Acid: A Review. *Biotechnol. Adv.* **2008**, *26*, 335–351. [CrossRef]
57. Drug Banck Online. Sulbactam: Uses, Interactions, Mechanism of Action. Available online: <https://go.drugbank.com/drugs/DB09324> (accessed on 10 February 2022).
58. Totir, M.A.; Helfand, M.S.; Carey, M.P.; Sheri, A.; Buynak, J.D.; Bonomo, R.A.; Carey, P.R. Sulbactam Forms Only Minimal Amounts of Irreversible Acrylate-Enzyme with SHV-1 β -Lactamase. *Biochemistry* **2007**, *46*, 8980–8987. [CrossRef]
59. Helfand, M.S.; Totir, M.A.; Carey, M.P.; Hujer, A.M.; Bonomo, R.A.; Carey, P.R. Following the Reactions of Mechanism-Based Inhibitors with β -Lactamase by Raman Crystallography. *Biochemistry* **2003**, *42*, 13386–13392. [CrossRef]
60. Drug Banck Online. Tazobactam: Uses, Interactions, Mechanism of Action. Available online: <https://go.drugbank.com/drugs/DB01606> (accessed on 10 February 2022).
61. Papp-Wallace, K.M.; Bethel, C.R.; Caillon, J.; Barnes, M.D.; Potel, G.; Bajaksouzian, S.; Rutter, J.D.; Reghal, A.; Shapiro, S.; Taracila, M.A.; et al. Beyond Piperacillin-Tazobactam: Cefepime and AAI101 as a Potent β -Lactam- β -Lactamase Inhibitor Combination. *Antimicrob. Agents Chemother.* **2019**, *63*, e00105-19. [CrossRef] [PubMed]
62. Vázquez-Ucha, J.C.; Arca-Suárez, J.; Bou, G.; Beceiro, A. New Carbapenemase Inhibitors: Clearing the Way for the β -Lactams. *Int. J. Mol. Sci.* **2020**, *21*, 9308. [CrossRef] [PubMed]
63. Tebipenem. Available online: <https://en.wikipedia.org/wiki/Tebipenem> (accessed on 10 February 2022).
64. Gallagher, G.M. Positive Results for Cefepime-Enmetazobactam in Phase 3 Trial. 28 February 2020. Available online: <https://www.contagionlive.com/view/positive-results-for-cefepimeenmetazobactam-in-phase-3-trial> (accessed on 10 February 2022).
65. Crandon, J.L.; Nicolau, D.P. In Vitro Activity of Cefepime/AAI101 and Comparators against Cefepime Non-Susceptible Enterobacteriaceae. *Pathogens* **2015**, *4*, 620–625. [CrossRef] [PubMed]
66. Morrissey, I.; Magnet, S.; Hawser, S.; Shapiro, S.; Knechtle, P. In Vitro Activity of Cefepime-Enmetazobactam against Gram-Negative Isolates Collected from U.S. and European Hospitals during 2014–2015. *Antimicrob. Agents Chemother.* **2019**, *63*, e00514-19. [CrossRef]
67. Crandon, J.L.; Nicolau, D.P. In Vivo Activities of Simulated Human Doses of Cefepime and Cefepime-AAI101 against Multidrug-Resistant Gram-Negative Enterobacteriaceae. *Antimicrob. Agents Chemother.* **2015**, *59*, 2688–2694. [CrossRef]
68. Weiss, W.J.; Petersen, P.J.; Murphy, T.M.; Tardio, L.; Yang, Y.; Bradford, P.A.; Venkatesan, A.M.; Abe, T.; Isoda, T.; Mihira, A.; et al. In Vitro and In Vivo Activities of Novel 6-Methylidene Penems as β -Lactamase Inhibitors. *Antimicrob. Agents Chemother.* **2004**, *48*, 4589–4596. [CrossRef]
69. ProbeChem. LN-1-255. Available online: http://www.probechem.com/products_LN-1-255.aspx (accessed on 10 February 2022).
70. Vázquez-Ucha, J.C.; Martínez-Gutián, M.; Maneiro, M.; Conde-Pérez, K.; Álvarez-Fraga, L.; Torrens, G.; Oliver, A.; Buynak, J.D.; Bonomo, R.A.; Bou, G.; et al. Therapeutic Efficacy of LN-1-255 in Combination with Imipenem in Severe Infection Caused by Carbapenem-Resistant *Acinetobacter Baumannii*. *Antimicrob. Agents Chemother.* **2019**, *63*, e01092-19. [CrossRef]
71. Rodríguez, D.; Maneiro, M.; Vázquez-Ucha, J.C.; Beceiro, A.; González-Bello, C. 6-Arylmethylidene Penicillin-Based Sulfone Inhibitors for Repurposing Antibiotic Efficiency in Priority Pathogens. *J. Med. Chem.* **2020**, *63*, 3737–3755. [CrossRef]

72. Drug Banck Online. Avibactam: Uses, Interactions, Mechanism of Action. Available online: <https://go.drugbank.com/drugs/DB09060> (accessed on 10 February 2022).
73. Livermore, D.M.; Meunier, D.; Hopkins, K.L.; Doumith, M.; Hill, R.; Pike, R.; Staves, P.; Woodford, N. Activity of Cef-tazidime/Avibactam against Problem Enterobacteriaceae and Pseudomonas Aeruginosa in the UK, 2015–2016. *J. Antimicrob. Chemother.* **2018**, *73*, 648–657. [CrossRef]
74. Ehmann, D.E.; Jahić, H.; Ross, P.L.; Gu, R.-F.; Hu, J.; Durand-Réville, T.F.; Lahiri, S.; Thresher, J.; Livchak, S.; Gao, N.; et al. Kinetics of Avibactam Inhibition against Class A, C, and D β -Lactamases. *J. Biol. Chem.* **2013**, *288*, 27960–27971. [CrossRef] [PubMed]
75. Shirley, M. Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections. *Drugs* **2018**, *78*, 675–692. [CrossRef] [PubMed]
76. Karlowsky, J.A.; Kazmierczak, K.M.; de Jonge, B.L.M.; Hackel, M.A.; Sahm, D.F.; Bradford, P.A. In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas Aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015. *Antimicrob. Agents Chemother.* **2017**, *61*, e00472-17. [CrossRef] [PubMed]
77. Shields, R.K.; Doi, Y. Aztreonam Combination Therapy: An Answer to Metallo- β -Lactamase-Producing Gram-Negative Bacteria? *Clin. Infect. Dis.* **2020**, *71*, 1099–1101. [CrossRef] [PubMed]
78. Lee, M.; Abbey, T.; Biagi, M.; Wenzler, E. Activity of Aztreonam in Combination with Ceftazidime-Avibactam against Serine- and Metallo- β -Lactamase-Producing Pseudomonas Aeruginosa. *Diagn. Microbiol. Infect. Dis.* **2020**, *99*, 115227. [CrossRef]
79. Drug Banck Online. Relebactam: Uses, Interactions, Mechanism of Action. Available online: <https://go.drugbank.com/drugs/DB12377> (accessed on 10 February 2022).
80. Campanella, T.A.; Gallagher, J.C. A Clinical Review and Critical Evaluation of Imipenem—Relebactam: Evidence to Date. *Infect. Drug Resist.* **2020**, *13*, 4297–4308. [CrossRef]
81. McCarthy, M.W. Clinical Pharmacokinetics and Pharmacodynamics of Imipenem_Cilastatin/Relebactam Combination Therapy. *Clin. Pharmacokinet.* **2020**, *59*, 567–573. [CrossRef]
82. PubChem. Zidebactam. Available online: <https://pubchem.ncbi.nlm.nih.gov/compound/77846445> (accessed on 10 February 2022).
83. Drug Banck Online. Zidebactam: Uses, Interactions, Mechanism of Action. Available online: <https://go.drugbank.com/drugs/DB13090> (accessed on 10 February 2022).
84. Karlowsky, J.A.; Hackel, M.A.; Bouchillon, S.K.; Sahm, D.F. In Vitro Activity of WCK 5222 (Cefepime-Zidebactam) against Worldwide Collected Gram-Negative Bacilli Not Susceptible to Carbapenems. *Antimicrob. Agents Chemother.* **2020**, *64*, e01432-20. [CrossRef]
85. Preston, R.A.; Mamikonyan, G.; DeGraff, S.; Chiou, J.; Kemper, C.J.; Xu, A.; Mastim, M.; Yeole, R.; Chavan, R.; Patel, A.; et al. Single-Center Evaluation of the Pharmacokinetics of WCK 5222 (Cefepime-Zidebactam Combination) in Subjects with Renal Impairment. *Antimicrob. Agents Chemother.* **2018**, *63*, e01484-18. [CrossRef]
86. Drug Banck Online. Durlobactam: Uses, Interactions, Mechanism of Action. Available online: <https://go.drugbank.com/drugs/DB16704> (accessed on 10 February 2022).
87. Shapiro, A.B.; Gao, N.; Jahić, H.; Carter, N.M.; Chen, A.; Miller, A.A. Reversibility of Covalent, Broad-Spectrum Serine β -Lactamase Inhibition by the Diazabicyclooctenone ETX2514. *ACS Infect. Dis.* **2017**, *3*, 833–844. [CrossRef]
88. McLeod, S.M.; Shapiro, A.B.; Moussa, S.H.; Johnstone, M.; McLaughlin, R.E.; de Jonge, B.L.M.; Miller, A.A. Frequency and Mechanism of Spontaneous Resistance to Sulbactam Combined with the Novel β -Lactamase Inhibitor ETX2514 in Clinical Isolates of Acinetobacter Baumannii. *Antimicrob. Agents Chemother.* **2018**, *62*, e01576-17. [CrossRef] [PubMed]
89. Sagan, O.; Yakubsevitch, R.; Yanev, K.; Fomkin, R.; Stone, E.; Hines, D.; O'Donnell, J.; Miller, A.; Isaacs, R.; Srinivasan, S. Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis. *Antimicrob. Agents Chemother.* **2020**, *64*, e01506-19. [CrossRef] [PubMed]
90. Drug Banck Online. Nacubactam: Uses, Interactions, Mechanism of Action. Available online: <https://go.drugbank.com/drugs/DB15353> (accessed on 10 February 2022).
91. Mushtaq, S.; Vickers, A.; Woodford, N.; Haldimann, A.; Livermore, D.M. Activity of Nacubactam (RG6080/OP0595) Combinations against MBL-Producing Enterobacteriaceae. *J. Antimicrob. Chemother.* **2018**, *74*, 953–960. [CrossRef]
92. Okujava, R.; Garcia-Alcalde, F.; Haldimann, A.; Zampaloni, C.; Morrissey, I.; Magnet, S.; Kothari, N.; Harding, I.; Bradley, K. 1359. Activity of Meropenem/Nacubactam Combination against Gram-Negative Clinical Isolates: ROSCO Global Surveillance 2017. *Open Forum Infect. Dis.* **2018**, *5*, S416. [CrossRef]
93. Asempa, T.E.; Motos, A.; Abdelraouf, K.; Bissantz, C.; Zampaloni, C.; Nicolau, D.P. Meropenem–Nacubactam Activity against AmpC-Overproducing and KPC-Expressing Pseudomonas Aeruginosa in a Neutropenic Murine Lung Infection Model. *Int. J. Antimicrob. Agents* **2020**, *55*, 105838. [CrossRef]
94. Mallalieu, N.L.; Winter, E.; Fettner, S.; Patel, K.; Zwanziger, E.; Attley, G.; Rodriguez, I.; Kano, A.; Salama, S.M.; Mallalieu, N.L.; et al. Safety and Pharmacokinetic Characterization of Nacubactam, a Novel β -Lactamase Inhibitor, Alone and in Combination with Meropenem, in Healthy Volunteers. *Antimicrob. Agents Chemother.* **2020**, *64*, e02229-19. [CrossRef]
95. MedKoo Bioscience Inc. EDX1317 Sodium. Available online: <https://medkoo.com/products/30175> (accessed on 10 February 2022).
96. MedKoo Bioscience Inc. EDX0282. Available online: <https://www.medkoo.com/products/30174> (accessed on 10 February 2022).

97. Durand-Réville, T.F.; Comita-Prevoir, J.; Zhang, J.; Wu, X.; May-Dracka, T.L.; Romero, J.A.C.; Wu, F.; Chen, A.; Shapiro, A.B.; Carter, N.M.; et al. Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β -Lactamases. *J. Med. Chem.* **2020**, *63*, 12511–12525. [CrossRef]
98. Miller, A.A.; Shapiro, A.B.; McLeod, S.M.; Carter, N.M.; Moussa, S.H.; Tommasi, R.; Mueller, J.P. In Vitro Characterization of ETX1317, a Broad-Spectrum β -Lactamase Inhibitor That Restores and Enhances β -Lactam Activity against Multi-Drug-Resistant Enterobacteriales, Including Carbapenem-Resistant Strains. *ACS Infect. Dis.* **2020**, *6*, 1389–1397. [CrossRef]
99. Thomas Durand-Réville. Entasis Therapeutic. ETX0282, a Novel Oral Agent against Multidrug-Resistant Enterobacteriaceae. Available online: <https://www.entasistx.com/application/files/9815/1846/7744/ETX0282-ASM-Microbe-2017.pdf> (accessed on 10 February 2022).
100. MedKoo Bioscience Inc. WCK-5153. Available online: <https://www.medkoo.com/products/18787> (accessed on 10 February 2022).
101. Papp-Wallace, K.M.; Nguyen, N.Q.; Jacobs, M.R.; Bethel, C.R.; Barnes, M.D.; Kumar, V.; Bajaksouzian, S.; Rudin, S.D.; Rather, P.N.; Bhavsar, S.; et al. Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β -Lactamase Inhibitors and β -Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234. *J. Med. Chem.* **2018**, *61*, 4067–4086. [CrossRef]
102. MedKoo Bioscience Inc. WCK-4232 Sodium. Available online: <https://www.medkoo.com/products/18790> (accessed on 10 February 2022).
103. Mushtaq, S.; Vickers, A.; Woodford, N.; Livermore, D.M. WCK 4234, a Novel Diazabicyclooctane Potentiating Carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with Class A, C and D β -Lactamases. *J. Antimicrob. Chemother.* **2017**, *72*, 1688–1695. [CrossRef]
104. MedKoo Bioscience Inc. ANT3310. Available online: <https://www.medkoo.com/products/42472> (accessed on 10 February 2022).
105. Antabio Receives FDA Qualified Infectious Disease Product (QIDP) Designation for MEM-ANT3310, a Novel Broad-Spectrum Combination Therapy Targeting WHO's Priority Pathogens. Available online: <https://antabio.com/2020/05/06/antabio-receives-fda-qualified-infectious-disease-product-qidp-designation-for-mem-ant3310-a-novel-broad-spectrum-combination-therapy-targeting-whos-priority-pathogens/> (accessed on 10 February 2022).
106. MedChemExpress. GT-055 (LCB18-055). Available online: <https://www.medchemexpress.com/gt-055.html> (accessed on 10 February 2022).
107. Nguyen, L.P.; Pinto, N.A.; Vu, T.N.; Lee, H.; Cho, Y.L.; Byun, J.-H.; D'Souza, R.; Yong, D. In Vitro Activity of a Novel Siderophore-Cephalosporin, GT-1 and Serine-Type β -Lactamase Inhibitor, GT-055, against Escherichia Coli, Klebsiella Pneumoniae and Acinetobacter Spp. Panel Strains. *Antibiotics* **2020**, *9*, 267. [CrossRef] [PubMed]
108. Halasohoris, S.A.; Scarff, J.M.; Pysz, L.M.; Lembirik, S.; Lemmon, M.M.; Biek, D.; Hannah, B.; Zumbun, S.D.; Panchal, R.G. In Vitro and in Vivo Activity of GT-1, a Novel Siderophore Cephalosporin, and GT-055, a Broad-Spectrum β -Lactamase Inhibitor, against Biothreat and ESKAPE Pathogens. *J. Antibiot.* **2021**, *74*, 884–892. [CrossRef]
109. Drug Banck Online. Vaborbactam: Uses, Interactions, Mechanism of Action. Available online: <https://go.drugbank.com/drugs/DB12107> (accessed on 10 February 2022).
110. Hecker, S.J.; Reddy, K.R.; Totrov, M.; Hirst, G.C.; Lomovskaya, O.; Griffith, D.C.; King, P.; Tsivkovski, R.; Sun, D.; Sabet, M.; et al. Discovery of a Cyclic Boronic Acid β -Lactamase Inhibitor (RPX7009) with Utility vs. Class A Serine Carbapenemases. *J. Med. Chem.* **2015**, *58*, 3682–3692. [CrossRef] [PubMed]
111. Griffith, D.C.; Loutit, J.S.; Morgan, E.E.; Durso, S.; Dudley, M.N. Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β -Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects. *Antimicrob. Agents Chemother.* **2016**, *60*, 6326–6332. [CrossRef]
112. Griffith, D.C.; Rubino, C.M.; Loutit, J.S.; Morgan, E.E.; White, D.; Dudley, M.N. Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment. *Antimicrob. Agents Chemother.* **2018**, *62*, e02103-17.
113. Kaye, K.S.; Bhowmick, T.; Metallidis, S.; Bleasdale, S.C.; Sagan, O.S.; Stus, V.; Vazquez, J.; Zaitsev, V.; Bidair, M.; Chorvat, E.; et al. Effect of Meropenem-Vaborbactam vs. Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial. *J. Am. Med. Assoc.* **2018**, *319*, 788–799. [CrossRef] [PubMed]
114. Wunderink, R.G.; Giamarellou-Bourboulis, E.J.; Rahav, G.; Mathers, A.J.; Bassetti, M.; Vazquez, J.; Cornely, O.A.; Solomkin, J.; Bhowmick, T.; Bishara, J.; et al. Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial. *Infect. Dis. Ther.* **2018**, *7*, 439–455. [CrossRef]
115. Drug Banck Online. Taniborbactam: Uses, Interactions, Mechanism of Action. Available online: <https://go.drugbank.com/drugs/DB16338> (accessed on 10 February 2022).
116. Hamrick, J.C.; Docquier, J.-D.; Uehara, T.; Myers, C.L.; Six, D.A.; Chatwin, C.L.; John, K.J.; Vernacchio, S.F.; Cusick, S.M.; Trout, R.E.L.; et al. VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo- β -Lactamases, Restores Activity of Cefepime in Enterobacteriales and Pseudomonas aeruginosa. *Antimicrob. Agents Chemother.* **2020**, *64*, e01963-19. [CrossRef]
117. Dowell, J.A.; Dickerson, D.; Henkel, T. Safety and Pharmacokinetics in Human Volunteers of Taniborbactam (VNRX-5133), a Novel Intravenous β -Lactamase Inhibitor. *Antimicrob. Agents Chemother.* **2021**, *65*, e01053-21. [CrossRef]

118. Venatorx Pharmaceuticals. Cefepime-taniborbactam. Available online: <https://www.venatorx.com/cefepime-taniborbactam/> (accessed on 10 February 2022).
119. Castro, A.M. Drugs Approval International. VNRX-7145. Available online: <http://drugapprovalsint.com/vnrx-7145/> (accessed on 10 February 2022).
120. Trout, R.E.; Zulli, A.; Mesaros, E.; Jackson, R.W.; Boyd, S.; Liu, B.; Hamrick, J.; Daigle, D.; Chatwin, C.L.; John, K.; et al. Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β -Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes. *J. Med. Chem.* **2021**, *64*, 10155–10166. [[CrossRef](#)]
121. Venatorx Pharmaceuticals. Ceftibuten/VNRX-7145. Available online: <https://www.venatorx.com/ceftibuten-vnrx-7145> (accessed on 10 February 2022).
122. MedKoo Bioscience Inc. QPX7728. Available online: <https://www.medkoo.com/products/37690> (accessed on 10 February 2022).
123. Nelson, K.; Rubio-Aparicio, D.; Sun, D.; Dudley, M.; Lomovskaya, O. In Vitro Activity of the Ultrabroad-Spectrum-Beta-Lactamase Inhibitor QPX7728 against Carbapenem-Resistant Enterobacterales with Varying Intrinsic and Acquired Resistance Mechanisms. *Antimicrob. Agents Chemother.* **2020**, *64*, e00757-20. [[CrossRef](#)] [[PubMed](#)]
124. Lomovskaya, O.; Nelson, K.J.; Rubio-Aparicio, D.; Tsivkovski, R.; Sun, D.; Dudley, M.N. Impact of Intrinsic Resistance Mechanisms on Potency of QPX7728, a New Ultrabroad-Spectrum Beta-Lactamase Inhibitor of Serine and Metallo-Beta-Lactamases in Enterobacteriaceae, *Pseudomonas Aeruginosa*, and *Acinetobacter Baumannii*. *Antimicrob. Agents Chemother.* **2020**, *64*, e00552-20. [[CrossRef](#)] [[PubMed](#)]
125. Qpex Biopharma Initiates Phase 1 Clinical Trial of QPX7728 for Drug-Resistant Bacterial Infections. Available online: <https://pipelinereview.com/index.php/2020120476731/Small-Molecules/Qpex-Biopharma-Initiates-Phase-1-Clinical-Trial-of-QPX7728-for-Drug-Resistant-Bacterial-Infections.html> (accessed on 10 February 2022).
126. Sabet, M.; Tarazi, Z.; Griffith, D.C. In Vivo Activity of QPX7728, an Ultrabroad-Spectrum Beta-Lactamase Inhibitor, in Combination with Beta-Lactams against Carbapenem-Resistant *Klebsiella Pneumoniae*. *Antimicrob. Agents Chemother.* **2020**, *64*, e01267-20. [[CrossRef](#)] [[PubMed](#)]
127. Davies, D.T.; Leiris, S.; Zalacain, M.; Sprynski, N.; Castandet, J.; Bousquet, J.; Lozano, C.; Llanos, A.; Alibaud, L.; Vasa, S.; et al. Discovery of ANT3310, a Novel Broad-Spectrum Serine β -Lactamase Inhibitor of the Diazabicyclooctane Class, Which Strongly Potentiates Meropenem Activity against Carbapenem-Resistant Enterobacterales and *Acinetobacter Baumannii*. *J. Med. Chem.* **2020**, *63*, 15802–15820. [[CrossRef](#)]
128. Adis Insights. ANT 2681. Available online: <https://adisinsight.springer.com/drugs/800038680> (accessed on 10 February 2022).
129. Das, S.; Johnson, A.; McEntee, L.; Farrington, N.; Kirby, A.; Unsworth, J.; Jimenez-Valverde, A.; Kolamunnage-Dona, R.; Bousquet, J.; Alibaud, L.; et al. Pharmacodynamics of the Novel Metallo-c-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing *Enterobacteriaceae*. *Antimicrob. Agents Chemother.* **2020**, *64*, e01076-20. [[CrossRef](#)]
130. Zalacain, M.; Lozano, C.; Llanos, A.; Sprynski, N.; Valmont, T.; Piano, C.D.; Davies, D.; Leiris, S.; Sable, C.; Ledoux, A.; et al. Novel Specific Metallo- β -Lactamase Inhibitor ANT2681 Restores Meropenem Activity to Clinically Effective Levels against NDM-Positive *Enterobacterales*. *Antimicrob. Agents Chemother.* **2021**, *65*, e00203-21. [[CrossRef](#)]
131. Augmentin®. Available online: <https://www.bing.com/search?q=Augmentin%C2%AE&pc=0ADS&ptag=C7N3516A308CE7CCFF&form=CONBNT&conlogo=CT3210127> (accessed on 10 February 2022).
132. Timentin®. Available online: https://www.torinomedica.it/schede-farmaci/timentin_3000_mg__200_mg/ (accessed on 10 February 2022).
133. Clavucar®. Available online: <https://www.torinomedica.it/schede-farmaci/clavucar/> (accessed on 10 February 2022).
134. Zosyn®. Available online: <https://www.pfizermedicalinformation.com/en-us/zosyn/dosage-admin> (accessed on 10 February 2022).
135. Zerbaxa®. Available online: <https://www.torinomedica.it/schede-farmaci/Zerbaxa/> (accessed on 10 February 2022).
136. Unasyn®. Available online: <https://www.my-personaltrainer.it/Foglietti-illustrativi/Unasyn.html> (accessed on 10 February 2022).
137. Sultamicillin®. Available online: <https://www.mims.com/philippines/drug/info/sultamicillin> (accessed on 10 February 2022).
138. Sulperazon®. Available online: <https://omedicine.info/it/sulperazon.html> (accessed on 10 February 2022).
139. Recarbrio®. Available online: <https://www.torinomedica.it/schede-farmaci/recarbrio/> (accessed on 10 February 2022).
140. Avycaz®. Available online: <https://www.avycaz.com/> (accessed on 10 February 2022).
141. Zavicefta®. Available online: <https://www.torinomedica.it/schede-farmaci/zavicefta/> (accessed on 10 February 2022).
142. Vaborem®. Available online: <https://www.torinomedica.it/schede-farmaci/vaborem/> (accessed on 10 February 2022).
143. Song, J.Y.; Jensen, S.E.; Lee, K.J. Clavulanic Acid Biosynthesis and Genetic Manipulation for Its Overproduction. *Appl. Microbiol. Biotechnol.* **2010**, *88*, 659–669. [[CrossRef](#)]
144. Chen, J.; Zhang, X. Method for Preparing Sulbactam Acid. Faming Zhuanli Shenqing CN 109705142, 3 May 2019.
145. Qin, S. Method for Synthesizing Tazobactam. Faming Zhuanli Shenqing CN 110357903, 4 September 2020.
146. Zhou, S.; Xin, Y.; Wang, J.; Wu, C.; Sun, T. Application of Continuous Flow in Tazobactam Synthesis. *Org. Process Res. Dev.* **2021**, *25*, 1648–1657. [[CrossRef](#)]
147. Peng, D.-M.; Li, Y.-X.; Liu, Y.-F.; Lu, M.-F.; Wang, F.-D. Synthesis of tebipenem pivoxil. *Zhongguo Kangshengsu Zazhi* **2013**, *38*, 41–43.

148. Udayampalayam Palanisamy, S.; Gnanaprakasam, A.; Ganapathy, P.; Gohain, M.; Hariharan, V.; Rajagopal, S.; Paul-Satyaseela, M.; Solanki, S.S.; Devarajan, S. Preparation of 2-Substituted Methyl Penam Derivatives for the Treatment of Bacterial Infections. U.S. Patent Applications Publication No. US 20080015156 A1, 17 January 2008.
149. Udayampalayam Palanisamy, S.; Paul-Satyaseela, M.; Shridhar, N.; Gopalan, B.; Aravind, A.; Senthilnathan, M.; Hariharan, P. β -Lactamase Inhibitors and Their Use as Antimicrobial Agents. PCT International Applications No. WO 2012070071 A1, 31 May 2012.
150. Faini, A.; Forzatti, M.; Fogliato, G.; Biondi, S. Method of Forming Methylpenam Triazolyl Derivatives as β -Lactamase Inhibitors. PCT International Applications No. WO 2015173378 A2, 19 November 2015.
151. Venkatesan, A.M.; Agarwal, A.; Abe, T.; Ushiroguchi, H.; Yamamura, I.; Kumagai, T.; Petersen, P.J.; Weiss, W.J.; Lenoy, E.; Yang, Y.; et al. Novel Imidazole Substituted 6-Methylidene-Penam as Broad-Spectrum β -Lactamase Inhibitors. *Bioorganic Med. Chem.* **2004**, *12*, 5807–5817. [[CrossRef](#)]
152. Osborne, N.F.; Broom, N.J.P.; Coulton, S.; Harbridge, J.B.; Harris, M.A.; Stirling-François, I.; Walker, G. A Novel and Stereocontrolled Synthesis of (5R)-(Z)-6-(1-Methyl-1,2,3-Triazol-4-ylmethylene)Penem-3-Carboxylic Acid, a Potent Broad Spectrum β -Lactamase Inhibitor. *J. Chem. Soc. Chem. Commun.* **1989**, *6*, 371–373. [[CrossRef](#)]
153. Buynak, J.D.; Rao, A.S.; Doppalapudi, V.R.; Adam, G.; Petersen, P.J.; Nidamarthy, S.D. The Synthesis and Evaluation of 6-Alkylidene-2' β -Substituted Penam Sulfones as β -Lactamase Inhibitors. *Bioorganic Med. Chem. Lett.* **1999**, *9*, 1997–2002. [[CrossRef](#)]
154. Edoo, Z.; Iannazzo, L.; Compain, F.; Li de la Sierra Gallay, I.; van Tilbeurgh, H.; Fonvielle, M.; Bouchet, F.; Le Run, E.; Mainardi, J.-L.; Arthur, M.; et al. Synthesis of Avibactam Derivatives and Activity on β -Lactamases and Peptidoglycan Biosynthesis Enzymes of Mycobacteria. *Chem. A Eur. J.* **2018**, *24*, 8081–8086. [[CrossRef](#)] [[PubMed](#)]
155. Peilleron, L.; Cariou, K. Synthetic Approaches towards Avibactam and Other Diazabicyclooctane β -Lactamase Inhibitors. *Org. Biomol. Chem.* **2020**, *18*, 830–844. [[CrossRef](#)] [[PubMed](#)]
156. Miller, S.P.; Limanto, J.; Zhong, Y.-L.; Yasuda, N.; Liu, Z. Preparation of Tert-Butyl-4-((1R,2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-Carboxamido Piperidine-1-Carboxylate. Application No. AU 2014278556 B2. WO20142007, 19 July 2018.
157. Maiti, S.N.; Nguyen, D.; Khan, J.; Ling, R. Preparation of 1,6-diazabicyclo[3.2.1]octane-2-carboxamide Compounds and Their Use as Antibacterial agents and Beta-Lactamase Inhibitors. PCT International Applications No. WO 2014091268 A1, 19 June 2014.
158. Liu, B.; Trout, R.E.L.; Chu, G.-H.; McGarry, D.; Jackson, R.W.; Hamrick, J.C.; Daigle, D.M.; Cusick, S.M.; Pozzi, C.; De Luca, F.; et al. Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo- β -Lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections. *Antimicrob. Agents Chemother.* **2020**, *63*, 2789–2801. [[CrossRef](#)] [[PubMed](#)]
159. Hecker, S.J.; Reddy, K.R.; Lomovskaya, O.; Griffith, D.C.; Rubio-Aparicio, D.; Nelson, K.; Tsivkovski, R.; Sun, D.; Sabet, M.; Tarazi, Z.; et al. Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo- β -Lactamases. *Antimicrob. Agents Chemother.* **2020**, *63*, 7491–7507. [[CrossRef](#)]
160. Davies, D.T.; Leiris, S.; Sprynski, N.; Castandet, J.; Lozano, C.; Bousquet, J.; Zalacain, M.; Vasa, S.; Dasari, P.K.; Pattipati, R.; et al. ANT2681: SAR Studies Leading to the Identification of a Metallo- β -Lactamase Inhibitor with Potential for Clinical Use in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae. *ACS Infect. Dis.* **2020**, *6*, 2419–2430. [[CrossRef](#)] [[PubMed](#)]